Annual Statements Open main menu

Mosaic ImmunoEngineering Inc. - Quarter Report: 2007 November (Form 10-Q)

patriot_10q-113007.htm
 


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q


(Mark One)
 
x
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended November 30, 2007
 
OR
 
o
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___________ to _______________
 
Commission File Number 0-22182
 
PATRIOT SCIENTIFIC CORPORATION
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation or organization)
84-1070278
(I.R.S. Employer Identification No.)

6183 Paseo Del Norte, Suite 180, Carlsbad, California
(Address of principal executive offices)
92011
(Zip Code)

(Issuer’s telephone number): (760) 547-2700

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES x   NO o
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer.  See definition of “accelerated filer and large accelerated filer” in Rule 12b-2 of the Exchange Act.  (Check one):
 
Large accelerated filer o                                                                Accelerated filer x                                                      Non-accelerated filer o
 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
 
Yes o  No x
 
On January 4, 2008, 391,472,101 shares of common stock, par value $.00001 per share (the issuer’s only class of voting stock) were outstanding.
 




INDEX


 
 
Page
PART I. FINANCIAL INFORMATION
 
ITEM 1. Financial Statements
 
Condensed consolidated Balance Sheets as of November 30, 2007 (unaudited) and May 31, 2007
3
Condensed consolidated Statements of Operations for the three and six months ended November 30, 2007 and 2006 (unaudited)
4
Condensed consolidated Statements of Cash Flows for the six months ended November 30, 2007 and 2006 (unaudited)
5
Notes to Condensed consolidated Financial Statements (unaudited)
6-21
ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
22-32
ITEM 3. Quantitative and Qualitative Disclosures About Market Risk
32
ITEM 4. Controls and Procedures
32
 
PART II. OTHER INFORMATION
 
ITEM 1. Legal Proceedings
33
ITEM 1A. Risk Factors
33
ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds
33
ITEM 3. Defaults Upon Senior Securities
33
ITEM 4. Submission of Matters to a Vote of Security Holders
34
ITEM 5. Other Information
34
ITEM 6. Exhibits
34-36
   
SIGNATURES
 
 
2


PART I- FINANCIAL INFORMATION

Item 1. Financial Statements

Patriot Scientific Corporation
Condensed Consolidated Balance Sheets

   
November 30,
2007
   
May 31,
2007
 
ASSETS
 
(Unaudited)
       
             
Current assets:
           
Cash and cash equivalents
  $
7,576,343
    $
21,605,428
 
Restricted cash and cash equivalents
   
50,487
     
102,346
 
Marketable securities and short term investments
   
12,629,946
     
4,349,314
 
Accounts receivable
   
421,050
     
352,390
 
Receivable from affiliated company
   
210,584
     
-
 
Note receivable
   
50,000
     
-
 
Inventory
   
312,514
     
46,361
 
Prepaid income taxes
   
-
     
2,070,981
 
Deferred tax assets
   
1,051,653
     
2,439,975
 
Prepaid expenses and other current assets
   
256,135
     
431,840
 
                 
Total current assets
   
22,558,712
     
31,398,635
 
                 
Property and equipment, net
   
80,374
     
85,518
 
                 
Other assets, net
   
8,190
     
8,190
 
                 
Investment in affiliated company
   
-
     
2,883,969
 
                 
Patents and trademarks, net of accumulated amortization of $613,246 and $607,657
   
32,728
     
38,317
 
    $
22,680,004
    $
34,414,629
 
                 
LIABILITIES AND STOCKHOLDERS’ EQUITY
               
                 
Current liabilities:
               
Accounts payable
  $
455,141
    $
934,298
 
Accrued expenses and other
   
213,518
     
1,086,496
 
Income taxes payable
   
5,446,572
     
-
 
                 
Total current liabilities
   
6,115,231
     
2,020,794
 
                 
Distributions in excess of  investment in affiliated company
   
568,605
     
-
 
Deferred tax liabilities
   
736,259
     
12,222,944
 
Total liabilities
   
7,420,095
     
14,243,738
 
                 
Commitments and contingencies
               
                 
Minority Interest
   
-
     
-
 
                 
Stockholders’ equity:
               
Preferred stock, $0.00001 par value; 5,000,000 shares authorized: none outstanding
   
-
     
-
 
Common stock, $0.00001 par value: 500,000,000 shares authorized: 410,638,449 shares issued and 391,472,101 shares outstanding at November 30, 2007 and 406,668,661 shares issued and 393,201,134 shares outstanding at May 31, 2007
   
4,106
     
4,066
 
Additional paid-in capital
   
69,828,330
     
72,150,581
 
Accumulated deficit
    (42,697,528 )     (43,151,678 )
Common stock held in treasury, at cost – 19,166,348 shares and 13,467,527 shares at November 30, 2007 and May 31, 2007,  respectively
    (11,874,999 )     (8,832,078 )
Total stockholders’ equity
   
15,259,909
     
20,170,891
 
    $
22,680,004
    $
34,414,629
 

 
See accompanying notes to unaudited condensed consolidated financial statements.

3

 
Patriot Scientific Corporation
Condensed Consolidated Statements of Operations
(Unaudited)

   
Three Months Ended
   
Six Months Ended
 
   
November 30, 2007
   
November 30, 2006
   
November 30, 2007
   
November 30, 2006
 
Revenues:
                       
Product sales and other
  $
945,830
    $
18,500
    $
1,467,199
    $
44,875
 
                                 
Cost of sales
   
356,338
     
-
     
507,873
     
-
 
Gross profit
   
589,492
     
18,500
     
959,326
     
44,875
 
                                 
Operating expenses:
                               
Selling, general and administrative
   
1,986,363
     
1,736,422
     
3,944,553
     
4,468,946
 
Settlement and license expense
   
388,660
     
6,300,000
     
418,660
     
6,300,000
 
Total operating expenses
   
2,375,023
     
8,036,422
     
4,363,213
     
10,768,946
 
Operating loss
    (1,785,531 )     (8,017,922 )     (3,403,887 )     (10,724,071 )
                                 
Other income (expense):
                               
    Interest and other income
   
301,066
     
181,131
     
775,591
     
307,898
 
Loss on sale of assets
    (924 )    
-
      (1,269 )     (543 )
Interest expense
   
-
     
-
      (237 )    
-
 
Gain on sale of subsidiary interest
   
-
     
-
     
150,000
     
-
 
Equity in earnings of affiliated company
   
5,486,039
     
6,674,793
     
4,285,497
     
18,744,991
 
Total other income, net
   
5,786,181
     
6,855,924
     
5,209,582
     
19,052,346
 
                                 
Income (loss) before income taxes
   
4,000,650
      (1,161,998 )    
1,805,695
     
8,328,275
 
                                 
Provision for income taxes
   
1,584,114
     
720,000
     
1,351,545
     
4,220,000
 
                                 
Net income (loss)
  $
2,416,536
    $ (1,881,998 )   $
454,150
    $
4,108,275
 
                                 
Basic income per common share
  $
0.01
    $
-
    $
-
    $
0.01
 
                                 
Diluted income per common share
  $
0.01
    $
-
    $
-
    $
0.01
 
                                 
Weighted average number of common shares outstanding-basic
   
391,245,755
     
378,817,682
     
390,848,284
     
373,800,101
 
                                 
Weighted average number of common shares outstanding-diluted
   
392,627,522
     
378,817,682
     
393,814,090
     
419,862,437
 
 
 
See accompanying notes to unaudited condensed consolidated financial statements.

4

Patriot Scientific Corporation
Condensed Consolidated Statements of Cash Flows
(Unaudited)
 
   
Six months ended
 
   
November 30, 2007
   
November 30, 2006
 
             
Operating activities:
           
Net income
  $
454,150
    $
4,108,275
 
Adjustments to reconcile net income to net cash used in operating activities:
               
Amortization and depreciation
   
22,915
     
21,288
 
Expense related to extension of expiration date of stock options
   
-
     
324
 
Non cash compensation relating to issuance of stock options and vesting of  warrants
   
346,134
     
1,773,102
 
Accrued interest income added to investments
    (641 )     (1,258 )
Equity in earnings of affiliated company
    (4,285,497 )     (18,744,991 )
Loss on sale of assets
   
1,269
     
543
 
Value of stock issued in connection with legal settlement
   
100,000
     
-
 
Deferred income taxes
    (10,098,363 )    
-
 
Gain on VIE sale of portion of subsidiary interest
    (150,000 )    
-
 
Reversal of tax effect of exercise of options
    (25,645 )    
-
 
Changes in operating assets and liabilities:
               
Accounts receivable
    (279,244 )     (3,325 )
Inventory
    (266,153 )    
-
 
Prepaid and other assets
   
179,695
     
172,921
 
Prepaid income taxes
   
2,070,981
     
-
 
Accounts payable and accrued expenses
    (1,352,136 )     (390,512 )
Accrued contested fee payable
   
-
     
5,960,000
 
Income taxes payable
   
5,446,572
     
4,154,600
 
Net cash used in operating activities
    (7,835,963 )     (2,949,033 )
                 
Investing activities:
               
Proceeds from sales of short-term investments
   
6,800,159
     
4,024,395
 
Purchases of short-term investments
    (15,080,791 )     (4,158,346 )
Proceeds from sale of restricted investments
   
52,500
     
-
 
Purchases of property and equipment
    (17,566 )     (5,947 )
Proceeds from sale of property and equipment
   
125
     
-
 
Proceeds from VIE sale of portion of subsidiary interest
   
100,000
     
-
 
Investment in debt securities
   
-
      (350,000 )
Distributions from affiliated company
   
7,738,072
     
15,099,267
 
Net cash provided by (used in) investing activities
    (407,501 )    
14,609,369
 
                 
Financing activities:
               
Proceeds from exercise of common stock warrants and options
   
18,200
     
97,850
 
Repurchase of warrants
    (2,760,900 )    
-
 
Repurchase of common stock for treasury
    (3,042,921 )     (4,024,395 )
Net cash used in financing activities
    (5,785,621 )     (3,926,545 )
                 
Net increase (decrease) in cash and cash equivalents
    (14,029,085 )    
7,733,791
 
Cash and cash equivalents, beginning of period
   
21,605,428
     
3,984,240
 
Cash and cash equivalents, end of period
  $
7,576,343
    $
11,718,031
 
                 
Supplemental Disclosure of Cash Flow Information:
               
                 
Cash payments for interest
  $
237
    $
-
 
Cash payments for income taxes
  $
3,958,000
    $
65,400
 
                 
Supplemental Disclosure of  Non-Cash Investing and Financing Activities:
               
Cashless exercise of warrants
  $
25
    $
225
 
Cashless exercise of stock options
  $
10
    $
-
 
Note receivable issued in connection with VIE sale of portion of subsidiary interest
  $
50,000
    $
-
 
 
 
See accompanying notes to unaudited condensed consolidated financial statements.
 
5

 
Patriot Scientific Corporation
Notes to Unaudited Condensed Consolidated Financial Statements  
 
1.  Basis of Presentation and Summary of Significant Accounting Policies

The unaudited condensed consolidated financial statements of Patriot Scientific Corporation (the “Company”, “we”, “us” or “our”) presented herein have been prepared pursuant to the rules of the Securities and Exchange Commission (“SEC”) for quarterly reports on Form 10-Q and do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America. These financial statements should be read in conjunction with our audited consolidated financial statements and notes thereto included in our Report on Form 10-K for our fiscal year ended May 31, 2007.

In the opinion of management, the interim condensed consolidated financial statements reflect all adjustments of a normal recurring nature necessary for a fair presentation of the results for the interim periods presented.  Operating results for the six month period ended November 30, 2007 are not necessarily indicative of the results that may be expected for the year ending May 31, 2008.

Basis of Consolidation
The condensed consolidated statement of operations for the three and six months ended November 30, 2006 includes our accounts and those of our majority owned subsidiaries, Metacomp, Inc. and Plasma Scientific Corporation. The condensed consolidated balance sheet at May 31, 2007 and the condensed consolidated financial statements as of and for the three and six months ended November 30, 2007 include our accounts, those of our majority owned subsidiaries that are not considered variable interest entities (“VIE”s) and all VIEs for which we are the primary beneficiary. All significant intercompany accounts and transactions have been eliminated.

Consolidation of Affiliate
In January 2003, the Financial Accounting Standards Board (“FASB”) issued FASB Interpretation 46, Consolidation of Variable Interest Entities, an Interpretation of ARB No. 51 (“FIN 46”). In December 2003, the FASB modified FIN 46. FIN 46 provides a new framework for identifying VIEs and determining when a company should include the assets, liabilities, noncontrolling interests and results of activities of a VIE in its consolidated financial statements.

A VIE is a corporation, partnership, limited liability corporation, trust or any other legal structure used to conduct activities or hold assets that either (1) has an insufficient amount of equity to carry out its principal activities without additional subordinated financial support, (2) has a group of equity owners that are unable to make significant decisions about its activities, or (3) has a group of equity owners that do not have the obligation to absorb losses or the right to receive returns generated by its operations.

FIN 46 requires a VIE to be consolidated if a party with an ownership, contractual or other financial interest in the VIE is obligated to absorb a majority of the risk of loss from the VIE’s activities, is entitled to receive a majority of the VIE’s residual returns (if no party absorbs a majority of the VIE’s losses), or both. A variable interest holder that consolidates the VIE is called the primary beneficiary. Upon consolidation, the primary beneficiary generally must initially record all of the VIE’s assets, liabilities, and noncontrolling interests at fair value and subsequently account for the VIE as if it were consolidated based on majority voting interest.

FIN 46 was effective immediately for VIEs created after January 31, 2003. The provisions of FIN 46, as revised, were adopted as of December 31, 2003, for our interests in all VIEs. Beginning with the quarter ended May 31, 2007, we consolidated Scripps Secured Data, Inc. (“SSDI”) as SSDI was deemed a VIE and we determined that we were the primary beneficiary of SSDI.

Investment in Affiliated Company
We have a 50% interest in Phoenix Digital Solutions, LLC (see Note 5). This investment is accounted for using the equity method of accounting since the investment provides us the ability to exercise significant influence, but not control, over the investee. Significant influence is generally deemed to exist if we have an ownership interest in the voting stock of the investee of between 20% and 50%, although other factors, such as representation on the investee’s board of directors, are considered in determining whether the equity method of accounting is appropriate. Under the equity method of accounting, the investment, originally recorded at cost, is adjusted to recognize our share of net earnings or losses of the investee and is recognized in the consolidated statements of operations in the caption “Equity in earnings (loss) of affiliated company”.

 
6

 
Patriot Scientific Corporation
Notes to Unaudited Condensed Consolidated Financial Statements  


Investment in Affiliated Company, continued
 
We review our investment in affiliated company to determine whether events or changes in circumstances indicate that its carrying amount may not be recoverable. The primary factors we consider in our determination are the financial condition, operating performance and near term prospects of the investee. If the decline in value is deemed to be other than temporary, we would recognize an impairment loss.

Revenue Recognition
We recognize revenue from the sale of our product upon shipment to the customer, at which time title transfers and we have no further obligations. Fees for maintenance or support are recorded on a straight-line basis over the underlying period of performance. Revenue from technology license agreements is recognized at the time we enter into a contract and provide the customer with the licensed technology. At this point, we have performed all of our obligations under contract, the rights to our technology have been transferred and no significant performance obligations remain.

SSDI recognizes revenue upon shipment of its product and recognizes revenue on its short-term installation contracts as time and materials costs are incurred.

SSDI maintains an agreement with a distributor which accounts for the majority of SSDI’s product sales. This agreement provides for a limited product warranty for a period of one year from the date of sale to the end user. The warranty does not cover damage to the product after it has been delivered to the distributor. SSDI’s agreement with the distributor also allows the distributor the right to stock rotation whereby the distributor, on a six month basis, may return product for replacement products of the distributor’s choosing provided that the aggregate price of the replacement products is equal to the price of the original products returned. Such stock rotations shall not exceed 10% of the distributor’s purchases from SSDI in the prior twelve month period for any year and any single rotation shall not exceed 6% of the total rotational allowance for that year. The first stock rotation shall not occur before February 2008.

Shipping and Handling
Emerging Issues Task Force (“EITF”) Issue No. 00-10, Accounting for Shipping and Handling Fees and Costs, requires shipping and handling fees billed to customers to be classified as revenue and shipping and handling costs to be classified as either cost of sales or disclosed in the notes to the financial statements. SSDI includes shipping and handling fees billed to customers in net sales. Shipping and handling costs associated with inbound freight are included in cost of sales.

Net Income (Loss) Per Share
We apply Statement of Financial Accounting Standards (“SFAS”) No. 128, Earnings Per Share, for the calculation of "Basic" and "Diluted" earnings per share. Basic earnings per share includes no dilution and is computed by dividing income available to common stockholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share reflects the potential dilution of securities that could share in the earnings of an entity.  For the three months and six months ended November 30, 2007, 5,495,000 potentially dilutive common shares related to our outstanding warrants and options were not included in the calculation of diluted income per share as they had an anti-dilutive effect.  For the three months ended November 30, 2006, 40,690,194 potentially dilutive common shares related to our outstanding warrants and options were not included in the calculation of diluted loss per share as they had an anti-dilutive effect. For the six months ended November 30, 2006, 100,000 potentially dilutive common shares related to our outstanding warrants and options were not included in the calculation of diluted income per share as they had an anti-dilutive effect.

7

 
Patriot Scientific Corporation
Notes to Unaudited Condensed Consolidated Financial Statements  

Net Income (Loss) Per Share, continued

   
Three Months Ended November 30, 2007  
   
Numerator (Income)
   
Denominator (Shares)
   
Per Share Amount
Basic EPS:
               
Net income
  $
2,416,536
     
391,245,755
    $
0.01 
Diluted EPS:
                   
Effect of dilutive securities:
               
Options and warrants
   
-
     
1,381,767
     
Income available to common shareholders
  $
2,416,536
     
392,627,522
    $
0.01 

 
Three Months Ended November 30, 2006  
   
Numerator (Loss)
   
Denominator (Shares)
   
Per Share Amount
Basic EPS:
               
Net loss
  $ (1,881,998 )    
378,817,682
    $
-
 
Diluted EPS:
                   
Effect of dilutive securities:
             
Options and warrants
   
-
     
-
     
Loss available to common shareholders
  $ (1,881,998 )    
378,817,682
    $
-
 
                     

 
Six Months Ended November 30, 2007  
   
Numerator (Income)
   
Denominator (Shares)
   
Per Share Amount
Basic EPS:
               
Net income
  $
454,150
     
390,848,284
    $
-
 
Diluted EPS:
                   
Effect of dilutive securities:
             
Options and warrants
   
-
     
2,965,806
     
Income available to common shareholders
  $
454,150
     
393,814,090
    $
-
 
                     

   
Six Months Ended November 30, 2006  
   
Numerator (Income)
   
Denominator (Shares)
   
Per Share Amount
Basic EPS:
               
Net income
  $
4,108,275
     
373,800,101
    $
0.01
 
Diluted EPS:
                   
Effect of dilutive securities:
             
Options and warrants
   
-
     
46,062,336
     
Income available to common shareholders
  $
4,108,275
     
419,862,437
    $
0.01
 
 
8

 
Patriot Scientific Corporation
Notes to Unaudited Condensed Consolidated Financial Statements  
 
Minority Interest
Minority interest in our consolidated financial statements results from the accounting for the acquisition of a noncontrolling interest in SSDI. Noncontrolling interest represents a partially owned subsidiary’s income, losses, and components of other comprehensive income which should be attributed to the controlling and noncontrolling interests or other parties with a right or obligation that affects the attribution of comprehensive income or loss, on the basis of their contractual rights or obligations, if any, otherwise, on the basis of ownership interests.

The noncontrolling interest in SSDI, which we are required to consolidate as we are the primary beneficiary, has been reduced to zero due to the initial allocation of losses prior to the period in which we were required to consolidate. If a noncontrolling interest has been reduced to zero, the primary beneficiary must absorb any losses that are in excess of the value of the noncontrolling interest’s equity. For the period in which we are required to consolidate, March 27, 2007 through November 30, 2007 we absorbed $45,864 of SSDI’s losses as we are the primary beneficiary. The noncontrolling interest in any future profits will not be presented until all prior losses have been recovered.
 
Stock-Based Compensation
On June 1, 2006, we adopted the provisions of SFAS No. 123(R), Share-Based Payment, which establishes standards for the accounting of transactions in which an entity exchanges its equity instruments for goods or services, primarily focusing on accounting for transactions where an entity obtains employee services in share-based payment transactions. SFAS No. 123(R) requires a public entity to measure the cost of employee services received in exchange for an award of equity instruments, including stock options, based on the grant-date fair value of the award and to recognize it as compensation expense over the period the employee is required to provide service in exchange for the award, usually the vesting period. Stock-based awards to non-employees are accounted for using the fair value method in accordance with SFAS No. 123, Accounting for Stock Based Compensation.
 
In November 2005, FASB issued FASB Staff Position No. FAS 123R-3, “Transition Election Related to Accounting for Tax Effects of Share-Based Payment Awards” (“FAS 123R-3”).  We have elected to adopt the alternative transition method provided in FAS 123R-3.  The alternative transition method includes a simplified method to establish the beginning balance of the additional paid-in capital pool (“APIC pool”) related to the tax effects of employee share-based compensation, which is available to absorb tax deficiencies recognized subsequent to the adoption of SFAS No. 123(R).
 
Stock-based compensation expense recognized during the period is based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Stock-based compensation expense recognized in our condensed consolidated statement of operations for the six months ended November 30, 2006 included compensation expense for share-based payment awards granted prior to, but not yet vested as of May 31, 2006 based on the grant date fair value estimated in accordance with the pro forma provisions of SFAS No. 123 and compensation expense for the share-based payment awards granted subsequent to May 31, 2006 based on the grant date fair value estimated in accordance with the provisions of SFAS No. 123(R). Stock-based compensation expense recognized in our condensed consolidated statement of operations for the six months ended November 30, 2007 included compensation expense for share-based payment awards granted subsequent to May 31, 2007 based on the grant date fair value estimated in accordance with the provisions of SFAS No. 123(R). As stock-based compensation expense recognized in the condensed consolidated statements of operations is based on awards ultimately expected to vest, it has been reduced for estimated forfeitures. SFAS No. 123(R) requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The estimated average forfeiture rate for the three and six months ended November 30, 2007 and 2006, of approximately 5% was based on historical forfeiture experience and estimated future employee forfeitures. The estimated pricing term of option grants for the three and six months ended November 30, 2007 and 2006 was five years.

9

 
Patriot Scientific Corporation
Notes to Unaudited Condensed Consolidated Financial Statements  
 
Stock-Based Compensation, continued
 
Summary of Assumptions and Activity

The fair value of stock-based awards to employees and directors is calculated using the Black-Scholes option pricing model, even though this model was developed to estimate the fair value of freely tradable, fully transferable options without vesting restrictions, which differ significantly from our stock options. The Black-Scholes model also requires subjective assumptions, including future stock price volatility and expected time to exercise, which greatly affect the calculated values. The expected term of options granted is derived from historical data on employee exercises and post-vesting employment termination behavior. The risk-free rate selected to value any particular grant is based on the U.S. Treasury rate that corresponds to the pricing term of the grant effective as of the date of the grant. The expected volatility for the three and six months ended November 30, 2007 and 2006 is based on the historical volatilities of our common stock.  These factors could change in the future, affecting the determination of stock-based compensation expense in future periods.

   
Three Months
Ended
 
Six Months
 Ended
 
Three Months
Ended
 
Six Months
Ended
   
November 30,
2007
(Unaudited)
 
November 30,
2007
(Unaudited)
 
November 30,
2006
(Unaudited)
 
November 30,
2006
(Unaudited)
                 
Expected term
   
5
 
years
   
4.4
 
years
   
5
 
years
   
5
 
years
Expected volatility
   
127
 
%
   
127-128
 
%
   
156
 
%
   
156
 
%
Risk-free interest rate
   
4.21
 
%
   
4.21 – 4.96
 
%
   
4.80
 
%
   
4.80 – 5.00
 
%
Expected dividends
   
2.82
 
%
   
2.82
 
%
   
-
       
-
   

A summary of option activity as of November 30, 2007 and changes during the six months then ended, is presented below:

   
Shares
   
Weighted Average Exercise Price
   
Weighted Average Remaining Contractual Term (Years)
   
Aggregate Intrinsic Value
 
Options outstanding at June 1, 2007
   
7,245,000
    $
0.40
             
Options granted
   
2,975,000
    $
0.47
             
Options exercised
    (1,107,846 )   $
0.16
             
Options forfeited
    (1,017,154 )   $
0.16
             
 
Options outstanding at November 30, 2007
   
8,095,000
    $
0.49
     
3.62
    $
1,237,700
 
 
Options vested and expected to vest at November 30, 2007
   
7,982,500
    $
0.49
     
3.61
    $
1,222,325
 
 
Options exercisable at November 30, 2007
   
5,845,000
    $
0.49
     
3.24
    $
930,200
 
 
10

 
Patriot Scientific Corporation
Notes to Unaudited Condensed Consolidated Financial Statements  
 
Stock-Based Compensation, continued
 
The weighted average grant date fair value of options granted during the six months ended November 30, 2007 and 2006 was $0.35 and $0.99 per option, respectively. The total intrinsic value of options exercised during the six months ended November 30, 2007 and 2006 was $513,550 and $169,500, respectively, based on the differences in market prices on the dates of exercise and the option exercise prices.

The aggregate intrinsic value represents the differences in market price at the close of the quarter ($0.61 per share on November 30, 2007) and the exercise price of outstanding, in the money options (those options with exercise prices below $0.61) on November 30, 2007.

As of November 30, 2007, there was approximately $662,167 of total unrecognized compensation cost related to employee stock option compensation arrangements.  That cost is expected to be recognized on a straight-line basis over the next 58 months.
 
The following table summarizes employee stock-based compensation expense related to stock options under SFAS No. 123(R) for the three and six months ended November 30, 2007 and 2006, which was recorded as follows:
 
   
Three Months Ended
   
Six Months
 Ended
   
Three Months Ended
   
Six Months
 Ended
 
   
November 30, 2007
   
November 30, 2007
   
November 30, 2006
   
November 30, 2006
 
Selling, general and administrative expense
  $
63,221
    $
346,134
    $
194,000
    $
1,770,000
 

Recent Accounting Pronouncements

In July 2006, the FASB issued Interpretation No. 48, Accounting for Uncertainty in Income Taxes - an interpretation of FASB Statement No. 109 (“FIN 48”). This interpretation clarifies the application of SFAS No. 109, Accounting for Income Taxes, by defining criteria that an individual tax position must meet for any part of the benefit of that position to be recognized in a company’s financial statements and also provides guidance on measurement, derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. We adopted FIN 48 on June 1, 2007 and did not record any cumulative effect adjustment to retained earnings as a result of adopting FIN 48.  Interest and penalties, if any, related to unrecognized tax benefits are recorded in income tax expense.  As of June 1, 2007, we are subject to U.S. Federal income tax examinations for the tax years May 31, 1991 through May 31, 2007, and we are subject to state and local income tax examinations for the tax years May 31, 1999 through May 31, 2007 due to the carryover of net operating losses from previous years.

In September 2006, the FASB issued SFAS No. 157, Fair Value Measurements (“SFAS No. 157”).  SFAS No. 157 defines fair value, establishes a framework for measuring fair value in generally accepted accounting principals and expands disclosures about fair value measurements.  The statement does not require new fair value measurements, but is applied to the extent that other accounting pronouncements require or permit fair value measurements.  The statement emphasizes that fair value is a market-based measurement that should be determined based on the assumptions that market participants would use in pricing an asset or liability.  Companies that have assets and liabilities measured at fair value will be required to disclose information that enables the users of its financial statements to access the inputs used to develop those measurements.  The reporting entity is encouraged, but not required, to combine the fair value information disclosed under this statement with the fair value information disclosed under other accounting pronouncements.  SFAS No. 157 is effective for fiscal years beginning after November 15, 2007. We expect to adopt SFAS No. 157 on June 1, 2008.  We are currently assessing the impact the adoption of SFAS No. 157 will have on our consolidated financial statements.

11


Patriot Scientific Corporation
Notes to Unaudited Condensed Consolidated Financial Statements  

Recent Accounting Pronouncements, continued

In February 2007, the FASB issued SFAS No. 159, The Fair Value Option for Financial Assets and Financial Liabilities (“SFAS No. 159”). SFAS No. 159 permits entities to choose to measure at fair value many financial instruments and certain other items that are not currently required to be measured at fair value. The objective is to improve financial reporting by providing entities with the opportunity to mitigate volatility in reported earnings caused by measuring related assets and liabilities differently without having to apply complex hedge accounting provisions. SFAS No. 159 also establishes presentation and disclosure requirements designed to facilitate comparisons between entities that choose different measurement attributes for similar types of assets and liabilities. SFAS No. 159 does not affect any existing accounting literature that requires certain assets and liabilities to be carried at fair value. SFAS No. 159 does not establish requirements for recognizing and measuring dividend income, interest income, or interest expense. This Statement does not eliminate disclosure requirements included in other accounting standards. SFAS No. 159 is effective in fiscal years beginning after November 15, 2007. We are in the process of evaluating the provisions of the statement, but do not anticipate that the adoption of SFAS No. 159 will have a material impact on our consolidated financial statements.

In December 2007, the FASB issued SFAS No. 141(R), Business Combinations (“SFAS No. 141(R)”). SFAS No. 141(R) requires acquiring entities in a business combination to recognize the assets acquired and liabilities assumed in the transaction; establishes the acquisition-date fair value as the measurement objective for all assets acquired and liabilities assumed; and requires the acquirer to disclose to investors the information they need to evaluate and understand the nature and financial effect of the business combination. SFAS No. 141(R) is effective in fiscal years beginning after December 15, 2008. We expect to adopt SFAS No. 141(R) on June 1, 2009.  We are currently assessing the impact the adoption of SFAS No. 141(R) will have on our consolidated financial statements.

In December 2007, the FASB issued SFAS No. 160, Noncontrolling Interests in Consolidated Financial Statements (“SFAS No. 160”). SFAS No. 160 requires entities to report noncontrolling (minority) interests in subsidiaries as equity in the consolidated financial statements . SFAS No. 160 is effective in fiscal years beginning after December 15, 2008. We expect to adopt SFAS No. 160 on June 1, 2009.  We are currently assessing the impact the adoption of SFAS No. 160 will have on our consolidated financial statements.

2. Cash, Cash Equivalents and Short-Term Investments

We consider all highly liquid investments with original maturities of three months or less to be cash equivalents.

Our short-term investments consist of money market mutual funds and auction rate securities and are reported at cost, which approximate fair market value.

During the quarter ended November 30, 2007 we had short-term investments in auction rate securities of  approximately $7.5 million.  Auction rate securities generally have long-stated maturities of 20 to 40 years.  These securities have certain economic characteristics of short-term investments due to a rate-setting mechanism and the ability to liquidate them through a Dutch auction process that occurs on pre-determined intervals of less than 90 days.  Due to the frequent resetting of interest rates, the carrying value of auction rate securities approximates fair value.

12

 
Patriot Scientific Corporation
Notes to Unaudited Condensed Consolidated Financial Statements  
 
3. Inventory

Inventory at November 30, 2007, consisted of raw materials of $87,462 and finished goods of $225,052.

4. License Agreements

In February 2005, we entered into two separate licensing agreements with one customer for our patent portfolio and Ignite microprocessor technology. The aggregate amount of the two licenses was $3,050,000, of which $2,950,000 was for licensing fees and $100,000 was for maintenance services. Maintenance under the agreement is expected to be provided over a period not to exceed four years. Maintenance revenue recognized during six months ended November 30, 2007 and 2006 was $12,500 and $12,500, respectively. The payment terms of the agreements required aggregate payments of $300,000 at the time of execution, three quarterly payments of $750,000 each on April 1, August 15, and November 15, 2005 and one final payment of $500,000 on February 15, 2006. The $500,000 payment due on February 15, 2006 was paid in March 2006. Total payments received in fiscal 2005 amounted to $1,050,000, and total payments received in fiscal 2006 amounted to $2,000,000. The agreements also provide for the future payment of royalties to us based on sales of product using the Ignite licensed technology. In connection with this license agreement, we became obligated to the co-inventor of the patent portfolio technology for $207,600 pursuant to a July 2004 agreement under which we were obligated to pay a percentage of all patent portfolio licensing proceeds to the co-inventor. The amount due under that license was payable in four installments of $51,900. The co-inventor of the patent portfolio technology filed a lawsuit against us seeking damages and/or enforcement of the July 2004 agreement. We challenged the enforceability of the agreement by counterclaim in that action. On February 14, 2007, a settlement of the litigation was finalized. Terms of the settlement required us to pay $3,400,000 in cash on February 14, 2007 and $3,000,000 on May 1, 2007, which amounted to approximately the debt claimed by the co-inventor to be owed to him under the July 2004 agreement. In addition, the settlement required us to make a donation of $15,000 on February 14, 2007 on behalf of Russell H. Fish III (“Fish”) to Maasai Power and Education Project, Inc., and to pay Fish the equivalent of 4% of 50% of the next $100 million of gross license fees as they are collected by Phoenix Digital and as distributions are made to us, after excluding the first $20 million collected by Phoenix Digital after December 1, 2006. Our commitment to make payments to Fish related to such future license revenues will not exceed $2 million. During the six months ended November 30, 2007, we recorded $418,660 in settlement and license expenses relating to royalty payments due to the Fish parties.

5. Investment in Affiliated Company/License Agreement

On June 7, 2005, we entered into a Master Agreement (the “Master Agreement”) with Technology Properties Limited Inc., a California corporation (“TPL”), and Charles H. Moore (“Moore”), the co-inventor of certain of our technology, pursuant to which we, TPL and Moore resolved all legal disputes between us. Pursuant to the Master Agreement, we and TPL entered into the Limited Liability Company Operating Agreement of Phoenix Digital (the “LLC Agreement”) into which we and Moore contributed our rights to certain of our technologies.

We and TPL each own 50% of the membership interests of Phoenix Digital, and each of us has the right to appoint one member of the three member management committee. The two appointees are required to select a mutually acceptable third member of the management committee. Pursuant to the LLC Agreement, we and TPL agreed to establish a working capital fund for Phoenix Digital of $4,000,000, of which our contribution was $2,000,000. The working capital fund increases to a maximum of $8,000,000 as license revenues are achieved. We and TPL are obligated to fund future working capital requirements at the discretion of the management committee of Phoenix Digital in order to maintain working capital of not more than $8,000,000. Neither we nor TPL are required to contribute more than $2,000,000 in any fiscal year. Distributable cash and allocation of profits and losses will be allocated to the members in the priority defined in the LLC Agreement.

13

 
Patriot Scientific Corporation
Notes to Unaudited Condensed Consolidated Financial Statements  
 
Investment in Affiliated Company/License Agreement, continued

Phoenix Digital has committed to pay a quarterly amount ranging between $500,000 and $1,000,000 (based upon a percentage of the working capital fund balance of Phoenix Digital) for supporting efforts to secure licensing agreements by the other member on behalf of Phoenix Digital. During the six months ended November 30, 2007 and 2006, Phoenix Digital paid $1,374,000 and $1,968,000, respectively, to TPL pursuant to this commitment.

We are accounting for our investment in Phoenix Digital under the equity method of accounting, and accordingly have recorded our share of Phoenix Digital’s net income of $4,285,497 during the six months ended November 30, 2007 and our share of Phoenix Digital’s net income of $18,744,991 during the six months ended November 30, 2006 as an increase in our investment. Cash distributions of $7,738,072 received from Phoenix Digital during the six months ended November 30, 2007 and cash distributions of $15,099,267 received from Phoenix Digital during the six months ended November 30, 2006 have been recorded as a reduction in our investment. During the three months ended November 30, 2007, Phoenix Digital distributed earnings in excess of the carrying amount of our investment of $568,605 at November 30, 2007.  Such amount has been recorded as “Distributions in Excess of Investment in Affiliated Company” due to our and TPL’s obligation to fund the working capital of Phoenix Digital at the discretion of Phoenix Digital’s management committee. We have recorded our share of Phoenix Digital’s net income as “Equity in Earnings of Affiliated Company” in the accompanying consolidated statements of operations for the six months ended November 30, 2007 and November 30, 2006. At November 30, 2007 we have recorded $210,584 as amounts receivable from affiliated company for reimbursement due to us of legal fees and related costs for the patent litigation (see Note 8).

During the six months ended November 30, 2007, Phoenix Digital entered into licensing agreements with third parties, pursuant to which it received aggregate proceeds of $20,933,000.  During the six months ended November 30, 2006, Phoenix Digital entered into licensing agreements with third parties, pursuant to which it received aggregate proceeds of $32,699,000.  License proceeds of $8,850,000 relating to an additional license agreement signed in November 2006 were received in January 2007.  Phoenix Digital had recorded this amount as a license receivable.

The condensed balance sheets and statements of operations of Phoenix Digital at November 30, 2007 and 2006 and for the six months then ended are as follows:

Condensed Balance Sheets

ASSETS:
 
 
2007
   
2006
 
Cash
  $
4,629,045
    $
7,731,427
 
License fees receivable
   
-
     
8,850,000
 
Prepaid expenses
   
95,000
     
15,000
 
Total assets
  $
4,724,045
    $
16,596,427
 

LIABILITIES AND MEMBERS’ EQUITY:

Accounts payable and accrued expenses
  $
5,849,465
    $
1,172,314
 
Income taxes payable
   
11,790
     
-
 
Members’ equity
    (1,137,210 )    
15,424,113
 
Total liabilities and members’ equity
  $
4,724,045
    $
16,596,427
 
 
14

 
Patriot Scientific Corporation
Notes to Unaudited Condensed Consolidated Financial Statements  
 
 
Investment in Affiliated Company/License Agreement, continued
 
Condensed Statements of Operations

   
2007
   
2006
 
                 
Revenues
  $
20,933,000
    $
41,549,000
 
Operating expenses
   
13,598,760
     
4,271,666
 
Operating income
   
7,334,240
     
37,277,334
 
Interest income
   
112,585
     
212,648
 
Net income
  $
7,446,825
    $
37,489,982
 

6. Consolidated Variable Interest Entity

On February 2, 2007, we invested an aggregate of $370,000 in SSDI for 2,100,000 shares of convertible preferred stock. This represents all of SSDI’s preferred stock and a 46% ownership interest in SSDI, a California corporation that manufactures products that protect information transmitted over secure networks. The investment consisted of certain assets contributed by us to SSDI valued at $250,000 and cash of $120,000. The shares are convertible at our option into shares of SSDI’s common stock on a one-to-one basis. The convertible preferred stock entitles us to receive non-cumulative dividends at the per annum rate of $0.04 per share, when and if declared by the Board of Directors of SSDI. The investment in SSDI’s convertible preferred stock also entitles us to a liquidation preference of $0.40 per share, plus an amount equal to all declared but unpaid dividends.

On March 27, 2007, we entered into an 18 month revolving line of credit with SSDI for a maximum amount of $500,000. The line of credit matures on September 27, 2008. If we do not provide notice to SSDI at least 90 days prior to the maturity date, the maturity date automatically extends 12 months. The line of credit is collateralized by all assets presently owned or hereafter acquired by SSDI. The carrying value of the collateral is approximately $547,390 at November 30, 2007. The creditors of SSDI do not have recourse to our other assets. On March 28, 2007, we advanced $150,000 under terms of the agreement, on April 16, 2007 we advanced $100,000 under terms of the agreement and on September 4, 2007 we advanced $100,000 under terms of the agreement.

The line of credit carries a floating interest rate which is defined as the prime rate as announced by Bank of America. At November 30, 2007, the interest rate on the note was 7.50%; On December 11, 2007, the interest rate on the note was 7.25%. SSDI is required to make minimum monthly payments on the line consisting of unpaid and accrued interest on the first day of the month following the initial advance.

As a result of the line of credit, we have a variable interest in SSDI, a variable interest entity, and we have determined that we are the primary beneficiary as we absorb more than half of the variable interest entity’s expected losses. FIN 46, requires us to consolidate SSDI as long as we are deemed to be the primary beneficiary. The equity interests of SSDI not owned by us are reported as a minority interest in our November 30, 2007 condensed consolidated balance sheet.  As of November 30, 2007, the noncontrolling interest in SSDI, which we are required to consolidate as we are the primary beneficiary, has been reduced to zero due to the initial allocation of losses prior to the period in which we were required to consolidate. If a noncontrolling interest has been reduced to zero, the primary beneficiary must absorb any losses that are in excess of the value of the noncontrolling interest’s equity. For the period in which we are required to consolidate, March 27, 2007 through November 30, 2007 we absorbed $45,864 of SSDI’s losses as we are the primary beneficiary. The noncontrolling interest in any future profits will not be presented until all prior losses have been recovered.

15

 
Patriot Scientific Corporation
Notes to Unaudited Condensed Consolidated Financial Statements  

Consolidated Variable Interest Entity, continued

Prior to initial consolidation, we recognized a $126,746 impairment loss on our investment for the losses of SSDI for the period February 2007 through March 26, 2007.

Upon initial consolidation of the variable interest entity, on March 27, 2007, $251,146 of current assets, $43,199 of net property and equipment, $47,240 of other assets, $98,331 of current liabilities and no minority interest were included on the consolidated balance sheet.

During the three months ended August 31, 2007, SSDI sold a membership interest in its subsidiary DataSecurus, LLC  to an unrelated third party for $100,000 in cash and a $50,000 note receivable due June 2008.

7.   Stockholders’ Equity

During July 2006 we commenced our Board of Director approved stock buyback program in which we repurchase our outstanding common stock from time to time on the open market.  As part of the program we purchased 5,698,821 and 4,874,827 shares of our common stock at an aggregate cost of $3,042,921 and $4,024,395 during the six months ended November 30, 2007 and 2006, respectively.

The following table summarizes equity transactions during the six months ended November 30, 2007:

   
Common Stock
   
Additional Paid-
   
Accumulated
   
Treasury
 
   
Shares
   
Amounts
   
 in Capital
   
 Deficit
   
 Stock
 
                               
Balance June 1, 2007
   
393,201,134
    $
4,066
    $
72,150,581
    $ (43,151,678 )   $ (8,832,078 )
                                         
Exercise of warrants and options at $0.05 to $0.10 per share
   
250,000
     
3
     
18,197
     
-
     
-
 
Cashless exercise of options
   
982,846
     
10
      (10 )    
-
     
-
 
Cashless exercise of warrants
   
2,536,942
     
25
      (25 )    
-
     
-
 
Issuance of stock
   
200,000
     
2
     
99,998
     
-
     
-
 
Repurchase of warrants
   
-
     
-
      (2,760,900 )    
-
     
-
 
Non-cash compensation
   
-
     
-
     
346,134
     
-
     
-
 
Tax effect of exercise of options
   
-
     
-
      (25,645 )    
-
     
-
 
Repurchase of common stock for treasury
    (5,698,821 )    
-
     
-
     
-
      (3,042,921 )
Net income
   
-
     
-
     
-
     
454,150
     
-
 
Balance November 30, 2007
   
391,472,101
    $
4,106
    $
69,828,330
    $ (42,697,528 )   $ (11,874,999 )

During November 2007 we issued 200,000 shares of our common stock to a former officer in connection with a settlement agreement (see Note 8).

Stock Options and Warrant Activity
 
As of November 30, 2007, we had 100,000 options outstanding pursuant to our 1996 Stock Option Plan exercisable at $0.07 per share expiring in 2009; 775,000 options outstanding pursuant to our 2001 Stock Option Plan exercisable at a range of $0.07 to $0.86 per share expiring through 2012; 3,350,000 options outstanding pursuant to our 2003 Stock Option Plan exercisable at a range of $0.05 to $0.49 per share expiring through 2012; and 3,870,000 options outstanding pursuant to our 2006 Stock Option Plan exercisable at a range of $0.45 to $0.70 per share expiring through 2012.  Some of the options outstanding under these plans are not presently exercisable and are subject to meeting vesting criteria.

During the quarter ended November 30, 2007, we issued options to acquire 750,000 shares of common stock to our newly appointed chief financial officer at an exercise price of $0.45 per share.

16

 
Patriot Scientific Corporation
Notes to Unaudited Condensed Consolidated Financial Statements  

Stockholders’ Equity, continued

During the six months ended November 30, 2007, directors exercised stock options to purchase 125,000 shares of common stock for proceeds of $11,950, and a director exercised stock options utilizing a share certification exchange procedure within our stock option plans to exercise 1,500,000 shares and receive 982,846 new shares upon exercise.

During the six months ended November 30, 2007, we recorded $346,134 of non cash compensation expense related to stock options issued and vesting of stock options.

As of November 30, 2007, we had warrants outstanding to purchase 500,000 common shares at exercise prices ranging from $0.06 to $1.00 per share, expiring at various dates through 2011.  During the six months ended November 30, 2007, we issued no warrants to purchase shares of common stock, an investor exercised warrants to purchase 125,000 shares of common stock for proceeds of $6,250, 1,898,973 warrants expired, 3,500,000 warrants were exercised utilizing the cashless method of exercise for 2,536,942 shares, and we repurchased 7,000,000 warrants for $2,760,900 under terms of our warrant repurchase agreement as detailed below.

In connection with a previous debt agreement, the Company entered into an Antidilution Agreement (the “Antidilution Agreement”) with Swartz Private Equity, LLC (“Swartz”) wherein the Company was obligated to issue to Swartz warrants equal to 11% of the common stock issued between January 28, 2002 and March 11, 2002, 20% of the common stock issued between March 12, 2002 and April 1, 2003, and after April 1, 2003, 30% of the common stock issued to any parties other than Swartz.  There were no warrants issued during the three month period ended August 31, 2006 in connection with the Antidilution agreement, nor were warrants issued during September 2006 in connection with the Antidilution agreement. On October 10, 2006, the Company entered into an Approval Rights Agreement and Termination of Antidilution Agreement and Addendum to Warrants (the “Termination Agreement”) with Swartz to terminate the Antidilution Agreement.  In consideration for entering into the Termination Agreement, the Company agreed that through May 31, 2008 it would obtain Swartz’s written approval at least 30 days prior to entering into (i) any acquisition of any business entity or asset of any kind where the aggregate number of shares of common stock and derivative securities (on a fully diluted basis) issued as consideration for the acquisition equals or exceeds 10% of the number of shares of common stock of the Company outstanding at the time of the acquisition (on a fully diluted basis) or (ii) any acquisition (regardless of size) by the Company of any business entity or asset of any kind that is not unanimously approved by the Company’s board of directors.

On July 19, 2007, we entered into a warrant redemption agreement with Lincoln Ventures, LLC, whereby at our option, we agreed to redeem certain warrants representing the right to acquire an aggregate of up to 7,000,000 shares of our common stock, through October 2007. The warrants were redeemable in quantities not to exceed 2,000,000 warrants in the first two calendar months and 3,000,000 in the last calendar month, at a price equal to the product of (a) the volume weighted average of the daily volume weighted average prices of our common stock for all trading days in the applicable calendar month, minus the exercise price of the warrant, multiplied by (b) the number of shares being redeemed from that warrant. Lincoln Ventures, LLC was prohibited from exercising any of the warrants as long as we remained in compliance with the agreement. Additionally, Lincoln Ventures, LLC was prohibited from purchasing any shares of our common stock on the open market during any “pricing month” defined in the agreement as the calendar month immediately preceding the calendar month in which we deliver the redemption notice to Lincoln Ventures, LLC.  As of November 30, 2007, we repurchased all of the additional warrants pursuant to the agreement.

17

 
Patriot Scientific Corporation
Notes to Unaudited Condensed Consolidated Financial Statements  

8.  Commitments and Contingencies

Litigation

Lowell Giffhorn Arbitration

On September 23, 2005, Lowell Giffhorn, a former executive officer and a former director of the Company, submitted a demand for arbitration with the American Arbitration Association related to the termination of Mr. Giffhorn's employment with the Company. Mr. Giffhorn asserted that the termination of his employment with the Company was unlawful, retaliatory, wrongful, violated public policy, violated the covenant of good faith and fair dealing and violated securities laws. Mr. Giffhorn sought damages of approximately $4,500,000 (excluding claims for punitive damages and attorney’s fees). On November 1, 2007, the Company and Mr. Giffhorn reached a settlement where Mr. Giffhorn was given $500,000 and 200,000 shares of restricted Company stock in exchange for a comprehensive release of all claims against the Company.  We have recorded these costs in selling, general and administrative expenses for the three and six months ended November 30, 2007.

Patent Litigation

Pursuant to the joint venture that the Company entered into in June 2005 with TPL (in settlement of inventorship/ownership litigation between the parties, and in return for a 50-50 sharing of net licensing and enforcement revenues), the Company granted TPL the complete and exclusive right to enforce and license its microprocessor patent portfolio. The Company then dismissed its patent infringement claims against Fujitsu Computer Systems, Inc. (“Fujitsu”), Matsushita Electric Corporation of America (“MEI”), NEC Solutions (America) Inc. (“NEC”), Sony Electronics Inc. (“Sony”), and Toshiba America Inc., and certain related entities of these defendants which had been pending in the Federal District Court for the Northern District of California. Thereafter, TPL, on behalf of the TPL/Patriot joint venture, filed patent infringement actions against certain of the foregoing defendants (except Sony) and their related entities in the Federal District Court for the Eastern District of Texas. Patriot was subsequently joined as a party to the litigation. Litigation was not reinitiated with regard to Fujitsu or NEC and certain of NEC’s subsidiaries as listed below.
 
In February 2006, a license agreement was entered into with Fujitsu regarding the Company's patent portfolio, and in connection with that transaction, litigation involving Fujitsu and TPL and the Company in both California and Texas was dismissed.

On August 25, 2006, ARM Ltd. and ARM, Inc. intervened as defendants, seeking a declaration of non-infringement of our ‘584 patent with respect to ARM processor cores contained within some alleged infringing chips of other defendants.

In February 2007, a license agreement was entered into with NEC Corporation, NEC Corporation of America, Inc., NEC Display Solutions of America, Inc. and NEC Unified Solutions, Inc. In connection with that transaction, the above named defendants, excluding NEC Electronics America, Inc., were dismissed from the lawsuit.

A Claims Construction Hearing was held May 3, 2007 in The United States District Court for the Eastern District of Texas. On June 15, 2007, the court handed down claims construction of the patents-in-suit, the ‘336, ‘148 and ‘584 patents. Based on the claims construction ruling, TPL/Patriot  proceeded with discovery with respect to the ‘336 and ‘148 patents. However, based on the claims construction ruling as to the ‘584 patent claims of “instruction groups”, TPL/Patriot announced on August 8, 2007, a Stipulation with ARM intended to expedite an appeal of that claims construction. The Stipulation was a declaration of non-infringement by the accused ARM products with respect to the ‘584 patent.  A notice of appeal to the Federal Circuit was filed with respect to the ARM Stipulation and the District Court’s claims construction with respect to the ‘584 patent.

18

 
Patriot Scientific Corporation
Notes to Unaudited Condensed Consolidated Financial Statements  

Commitments and Contingencies, continued

On December 18, 2007 all remaining parties to the litigation announced that a resolution was reached in the patent infringement lawsuits.  The terms of the settlement included the grant by TPL of rights under the Moore Microprocessor Patent Portfolio to NEC Electronics America, Toshiba, Matsushita and JVC and their respective subsidiaries in the form of license agreements.  The parties have agreed that the details of the settlement are confidential.

401(k) Plan

We have a retirement plan that complies with Section 401(k) of the Internal Revenue Code. All employees are eligible to participate in the plan. We match 50% of each participant’s voluntary contributions, subject to a maximum contribution of 6% of the participant’s compensation. Participants vest 33% per year over a three year period in our contributions. Our matching contributions during the six months ended November 30, 2007 and 2006 were $3,388 and $5,607, respectively.

Employment Contracts

In connection with Mr. Turley’s appointment as President and Chief Executive Officer, and commencing on June 5, 2007, we entered into an employment agreement with Mr. Turley for a one-year term.  Pursuant to the agreement, if Mr. Turley is terminated without cause, he is entitled to his then current salary level for the remaining term of his agreement conditional upon the execution of a general release.
 
In connection with Mr. Flowers’ appointment as the Chief Financial Officer, and commencing on September 17, 2007, we entered into an employment agreement with Mr. Flowers for an initial 120-day term if not terminated pursuant to the agreement, with an extension period of one year and on a continuing basis thereafter.  Pursuant to the agreement, if Mr. Flowers is terminated without cause or resigns with good reason within the first two years of employment, he is entitled to receive an amount equal to his annual base salary for the greater of (i) 6 months or (ii) the period remaining in the extended one-year term.  If Mr. Flowers is terminated without cause or resigns with good reason any time after two years of continuous employment, he is entitled to receive an amount equal to 12 months of his annual base salary.  Mr. Flowers is also entitled to certain payments upon a change of control of the Company if the surviving corporation does not retain him. All such payments are conditional upon the execution of a general release.

Guarantees and Indemnities

We have made certain guarantees and indemnities, under which we may be required to make payments to a guaranteed or indemnified party. We indemnify our directors, officers, employees and agents to the maximum extent permitted under the laws of the State of Delaware and California for SSDI. In connection with our facility leases, we have indemnified our lessors for certain claims arising from the use of the facilities. The duration of the guarantees and indemnities varies, and in many cases is indefinite. These guarantees and indemnities do not provide for any limitation of the maximum potential future payments we could be obligated to make. Historically, we have not been obligated to make any payments for these obligations and no liabilities have been recorded for these guarantees and indemnities in the accompanying consolidated balance sheets.

Operating Leases

We have a non-cancelable operating lease agreement for our Carlsbad, California office facility. Future minimum lease payments required under the operating lease are $48,447 and $73,710 in fiscal years ended 2008 and 2009, respectively.

19


Patriot Scientific Corporation
Notes to Unaudited Condensed Consolidated Financial Statements  
 
Commitments and Contingencies, continued

SSDI subleases their Carlsbad, California office facility which was amended to extend through June 2008 with a month-to-month option until no later than December 2008. Future minimum lease payments required under the operating lease are $44,324 and $7,351 in fiscal years ended 2008 and 2009, respectively.

SSDI also leases office space in Annapolis, Maryland on a month-to-month basis at $750 per month expiring February 2008. The lease may be terminated by either party with 30 days notice.

Earn-Out Agreement

SSDI entered into an earn-out agreement with a former debt holder of Holocom Networks, Inc. (“Holocom Networks”) upon our contribution of the foreclosure sale collateral of Holocom Networks to SSDI in fiscal 2007. The agreement required the former debt holder to release all of his rights to any Holocom Networks collateral in exchange for receiving 3% of the net sales (defined as cash revenues actually received less credits or discounts and other claims of customers) of SSDI’s protected distribution system products for a period of 48 months from the foreclosure sale date of February 2, 2007. The earn-out is to be paid each calendar quarter.  A liability for payment under this agreement of $9,032 is included in accrued expenses in the accompanying condensed consolidated balance sheet at November 30, 2007.

9. Segment Information

SSDI began operations in February 2007 and we consolidated SSDI in our financial statements in March 2007. SSDI is an operating segment under FASB Statement No. 131, Disclosures About Segments of an Enterprise, as revenue is 10% or more of the total revenue of all operating segments.

SSDI is engaged in the business of developing and manufacturing network-security hardware for sale to government, military, and other high-security facilities. There is no inter-segment revenue, and the accounting policies for segment reporting are the same as for us as a whole.

The “all other” category includes the results for Patriot Scientific Corporation.

Operating segment net revenue, operating loss and income (loss) before taxes for the three and six months ended November 30, 2007 and 2006 were as follows:

   
Three Months Ended
   
Six Months Ended
 
   
November 30, 2007
   
November 30, 2006
   
November 30, 2007
   
November 30, 2006
 
Net revenue:
                       
SSDI
  $
933,280
    $
-
    $
1,445,144
    $
-
 
All other
   
12,550
     
18,500
     
22,055
     
44,875
 
Total net revenue
  $
945,830
    $
18,500
    $
1,467,199
    $
44,875
 
                                 
Operating income (loss):
                               
SSDI
  $
120,587
    $
-
    $ (25,042 )   $
-
 
All other
    (1,906,118 )     (8,017,922 )     (3,378,845 )     (10,724,071 )
Total operating loss
  $ (1,785,531 )   $ (8,017,922 )   $ (3,403,887 )   $ (10,724,071 )
                                 
Income (loss) before taxes:
                               
SSDI
  $
119,299
    $
-
    $
124,048
    $
-
 
All other
   
3,881,351
      (1,161,998 )    
1,681,647
     
8,328,275
 
Total income (loss) before taxes
  $
4,000,650
    $ (1,161,998 )   $
1,805,695
    $
8,328,275
 

20

 
Patriot Scientific Corporation
Notes to Unaudited Condensed Consolidated Financial Statements  

Segment Information, continued

All sales were to unaffiliated customers within the United States. During the six months ended November 30, 2007, one customer accounted for 51% of SSDI’s sales and this same customer accounted for 27% of SSDI’s accounts receivable at November 30, 2007.  Another customer accounted for 17% of SSDI’s sales and this same customer accounted for 29% of SSDI’s accounts receivable at November 30, 2007.

Operating segment total assets and depreciation and amortization as of and for the six months ended November 30, 2007 and 2006 were as follows:

 
 
2007
   
2006
 
Depreciation and amortization:
 
 
   
 
 
SSDI
  $
8,525
    $
-
 
All other
   
14,390
     
21,288
 
Total depreciation and amortization
  $
22,915
    $
21,288
 
 
 
 
2007
   
2006
 
Total assets:
 
 
   
 
 
SSDI
  $
1,011,498
    $
-
 
All other
   
21,668,506
     
23,750,911
 
Total assets
  $
22,680,004
    $
23,750,911
 
 
10.  Subsequent Events

On December 11, 2007 the interest rate on our line of credit with SSDI decreased to 7.25% in accordance with the change in the prime interest rate.

On December 18, 2007 we received payment from Phoenix Digital Solutions for the amount shown as receivable from affiliated company on our November 30, 2007 consolidated balance sheet.

On December 18, 2007 all remaining parties to the litigation announced that a resolution was reached in the patent infringement lawsuits.  The terms of the settlement included the grant by TPL of rights under the Moore Microprocessor Patent Portfolio to NEC Electronics America, Toshiba, Matsushita and JVC and their respective subsidiaries in the form of license agreements.  The parties have agreed that the details of the settlement are confidential.

21

 
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

THE FOLLOWING DISCUSSION INCLUDES FORWARD-LOOKING STATEMENTS WITH RESPECT TO OUR FUTURE FINANCIAL PERFORMANCE. ACTUAL RESULTS MAY DIFFER MATERIALLY FROM THOSE CURRENTLY ANTICIPATED AND FROM HISTORICAL RESULTS DEPENDING UPON A VARIETY OF FACTORS, INCLUDING THOSE DESCRIBED BELOW UNDER THE SUB-HEADING, "RISK FACTORS" SEE ALSO OUR ANNUAL REPORT ON FORM 10-K FOR THE YEAR ENDED MAY 31, 2007.

Overview

In June 2005, we entered into a series of agreements with Technology Properties Limited, Inc. (“TPL”) and others to facilitate the pursuit of infringers of our intellectual property. We intend to continue our joint venture with TPL to pursue license agreements with infringers of our technology. We believe that utilizing the option of working through TPL, as compared to creating and using a Company licensing team for those activities, avoids a competitive devaluation of our principal assets and is a prudent way to achieve the desired results as we seek to obtain fair value from users of our intellectual property.

During the fiscal year ended May 31, 2006, we finalized an agreement for the licensing of our technology with Intel Corporation. During the fiscal years ended May 31, 2006 and 2007, TPL entered into licensing agreements with Hewlett-Packard, Fujitsu, Casio, Nikkon, Sony, Seiko Epson, Pentax, Olympus, Kenwood, Agilent Technologies, Schneider Electric, Lexmark, NEC, Funai Electric, SanDisk, Sharp and Nokia operating through our joint venture entity, Phoenix Digital Solutions, LLC (“PDS”).  During the six months ended November 30, 2007, TPL entered into licensing agreements with Bull, Lego Systems, DMP Electronics, Denso Wave, Bossiere (Schneider) and Philips. We believe that these agreements represent validation of our position that our intellectual property was and is being infringed by major manufacturers and users of microprocessor technology.

Critical Accounting Policies and Estimates

Our condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, which require us to make estimates and judgments that significantly affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. Actual results could differ from those estimates, and such differences could affect the results of operations reported in future periods. We believe the following critical accounting policies affect our most significant estimates and judgments used in the preparation of our condensed consolidated financial statements.
 
1.           Revenue Recognition

Accounting for revenue recognition is complex and affected by interpretations of guidance provided by several sources, including the Financial Accounting Standards Board (“FASB”) and the Securities and Exchange Commission (“SEC”). This guidance is subject to change. We follow the guidance established by the SEC in Staff Accounting Bulletin No. 104, as well as generally accepted criteria for revenue recognition, which require that, before revenue is recorded, there is persuasive evidence of an arrangement, the fee is fixed or determinable, collection is reasonably assured, and delivery to our customer has occurred. Applying these criteria to certain of our revenue arrangements requires us to carefully analyze the terms and conditions of our license agreements. Revenue from our technology license agreements is generally recognized at the time we enter into a contract and provide our customer with the licensed technology. We believe that this is the point at which we have performed all of our obligations under the agreement; however, this remains a highly interpretive area of accounting and future license agreements may result in a different method of revenue recognition. Fees for maintenance or support of our licenses are recorded on a straight-line basis over the underlying period of performance.

Our consolidated variable interest entity recognizes revenue upon shipment of its product and recognizes revenue on its short-term installation contracts as time and materials costs are incurred.

22

 
2.           Assessment of Contingent Liabilities

We are involved in various legal matters, disputes, and patent infringement claims which arise in the ordinary course of our business. We accrue for estimated losses at the time when we can make a reliable estimate of such loss and it is probable that it has been incurred. By their very nature, contingencies are difficult to estimate. We continually evaluate information related to all contingencies to determine that the basis on which we have recorded our estimated exposure is appropriate.

3.           Stock Options and Warrants
 
On June 1, 2006, we adopted the provisions of SFAS No. 123(R), Share-Based Payment, which establishes standards for the accounting of transactions in which an entity exchanges its equity instruments for goods or services, primarily focusing on accounting for transactions where an entity obtains employee services in share-based payment transactions. SFAS No. 123(R) requires a public entity to measure the cost of employee services received in exchange for an award of equity instruments, including stock options, based on the grant-date fair value of the award and to recognize it as compensation expense over the period the employee is required to provide service in exchange for the award, usually the vesting period.  Stock-based awards to non-employees are accounted for using the fair value method in accordance with SFAS No. 123, Accounting for Stock Based Compensation.
 
In November 2005, FASB issued FASB Staff Position No. FAS 123R-3, “Transition Election Related to Accounting for Tax Effects of Share-Based Payment Awards” (“FAS123R-3”).  We have elected to adopt the alternative transition method provided in FAS 123R-3.  The alternative transition method includes a simplified method to establish the beginning balance of the additional paid-in capital pool (“APIC pool”) related to the tax effects of employee share-based compensation, which is available to absorb tax deficiencies recognized subsequent to the adoption of SFAS No. 123(R).
 
Stock-based compensation expense recognized during the period is based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Stock-based compensation expense recognized in our condensed consolidated statement of operations for the six months ended November 30, 2006 included compensation expense for share-based payment awards granted prior to, but not yet vested as of May 31, 2006 based on the grant date fair value estimated in accordance with the pro forma provisions of SFAS No. 123 and compensation expense for the share-based payment awards granted subsequent to May 31, 2006 based on the grant date fair value estimated in accordance with the provisions of SFAS No. 123(R). Stock-based compensation expense recognized in our condensed consolidated statement of operations for the six months ended November 30, 2007 included compensation expense for share-based payment awards granted subsequent to May 31, 2007 based on the grant date fair value estimated in accordance with the provisions of SFAS No. 123(R). As stock-based compensation expense recognized in the condensed consolidated statements of operations is based on awards ultimately expected to vest, it has been reduced for estimated forfeitures. SFAS No. 123(R) requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The estimated average forfeiture rate for the six months ended November 30, 2007 and 2006, of approximately 5% was based on historical forfeiture experience and estimated future employee forfeitures.
 
Employee stock-based compensation expense recognized under SFAS No. 123(R) for the six months ended November 30, 2007 and 2006 was $346,134 and $1,770,000, respectively, as determined by the Black-Scholes valuation model.

4.           Patents and Trademarks

We carry our patents and trademarks at cost less accumulated amortization and we amortize the patents over their estimated useful lives of four years. We periodically review the carrying value of the patents and trademarks for impairment and recognize impairment when the expected future benefit to be derived from an individual intangible asset is less than its carrying value.

23

 
5.           Income Taxes

We must assess the likelihood that we will be able to recover our deferred tax assets. If recovery is not likely, we must increase our provision for taxes by recording a valuation allowance against the deferred tax assets that we estimate will not ultimately be recoverable. We believe that a substantial majority of the deferred tax assets recorded on our balance sheet will ultimately be recovered. However, should there be a change in our ability to recover the deferred tax assets; the tax provision would increase in the period in which we determined that the recovery was not probable.

6.
Investment in Affiliated Company

We have a 50% interest in PDS. We account for our investment using the equity method of accounting since the investment provides us the ability to exercise significant influence, but not control, over the investee. Significant influence is generally deemed to exist if we have an ownership interest in the voting stock of the investee of between 20% and 50%, although other factors, such as representation on the investee’s Board of Directors, are considered in determining whether the equity method of accounting is appropriate. Under the equity method of accounting, the investment, originally recorded at cost, is adjusted to recognize our share of net earnings or losses of the investee and is recognized in the consolidated statement of operations in the caption “Equity in earnings of affiliated company”.

We review our investment to determine whether events or changes in circumstances indicate that our carrying amount may not be recoverable. The primary factors we consider in our determination are the financial condition, operating performance and near term prospects of the investee. If a decline in value is deemed to be other than temporary, we would recognize an impairment loss.

7.          Variable Interest Entity

We own 100% of the preferred stock of Scripps Secured Data, Inc. (“SSDI”). On March 27, 2007 we entered into an 18 month revolving line of credit with SSDI for a maximum amount of $500,000. The line of credit caused us to have a variable interest in SSDI, a variable interest entity, and we have determined that we are the primary beneficiary as we absorb more than half of the variable interest entity’s expected losses. FIN46(R), Consolidation of Variable Interest Entities, requires us to consolidate SSDI as long as we are deemed to be the primary beneficiary.

We reevaluate our primary beneficiary position at each of our balance sheet dates using the guidance in FIN46(R). If we are no longer deemed to be the primary beneficiary of the variable interest entity, we will discontinue consolidation.

Results of Operations

Comparison of the Six Months Ended November 30, 2007 and Six Months Ended November 30, 2006.

Our revenues increased from approximately $45,000 for the six months ended November 30, 2006 to approximately $1,467,000 for the six months ended November 30, 2007. Our revenue amounts do not include income of approximately $18,745,000 from our investment in Phoenix Digital Solutions, LLC for the six months ended November 30, 2006, or income of approximately $4,285,000 from our investment in Phoenix Digital Solutions, LLC for the six  months ended November 30, 2007.  During the six months ended November 30, 2007 we recorded sales amounting to approximately $1,445,000 by our consolidated variable interest entity, SSDI, with cost of sales amounting to approximately $508,000. During the six months ended November 30, 2006 and 2007, we recognized maintenance fee revenues totaling approximately $12,500 and $12,500 in connection with an agreement with AMD Corporation during the 2005 fiscal year. The agreement called for maintenance fees totaling $100,000 connected with a license agreement for our Ignite technology; the license fee revenue is being recognized as revenue evenly over the four year period of the license. In addition during the six months ended November 30, 2007, we recorded sales of approximately $9,600 from the sale of microprocessor chips that we no longer market. Inventory associated with the sales of these microprocessor chips is carried at zero value.  During the six months ended November 30, 2006, we recorded sales of approximately $32,000 relating to the microprocessor chips.

24

 
Selling, general and administrative expenses decreased from approximately $4,469,000 for the six months ended November 30, 2006 to approximately $3,945,000 for the six months ended November 30, 2007.  Legal expenses increased by approximately $63,000 for the six months ended November 30, 2007 compared with the six months ended November 30, 2006 and accounting expenses decreased by approximately $228,000 for the six months ended November 30, 2007 compared with the six months ended November 30, 2006 the decrease was primarily due to restatement expenses incurred during the six months ended November 30, 2006. Salary costs and related expenses included non-cash expenses associated with the fair value of options granted during the period in accordance with SFAS No. 123R.  During the six months ended November 30, 2007, options were granted to our newly-appointed chief executive officer and chief financial officer pursuant to terms of their employment contracts, those option grants plus the related vesting on the grants resulted in non-cash compensation expense of approximately $233,000.  On August 16, 2007 options were granted to certain employees and a newly-appointed director resulting in non-cash compensation of approximately $113,000.  During the six months ended November 30, 2006, 1,500,000 options were granted to our then chief executive officer resulting in a non-cash compensation expense amounting to approximately $1,527,000 and options were granted to employees resulting in non-cash compensation of approximately $184,000.  Board of director fees amounting to approximately $212,000 were paid during the six months ended November 30, 2007 as compared to $150,000 paid for the six months ended November 30, 2006.  Other salary expenses increased by approximately $632,000 for the six months ended November 30, 2007 as compared with the six months ended November 30, 2006 including approximately $595,000 in salaries and related expenses for SSDI during the six months ended November 30, 2007. Salary expenses for the parent company including wages, payroll taxes, employee benefits and expenses connected with 401(k) employer matching increased by approximately $38,000 during the six months ended November 30, 2007 as compared with the six months ended November 30, 2006.  Travel and related expenses for the six months ended November 30, 2007 increased by approximately $99,000 due to expenses for SSDI being combined with the parent company.  Consulting expenses increased by approximately $33,000 for the six months ended November 30, 2007 as compared to the six months ended November 30, 2006 due to one time fees for evaluations of our various technologies and expenses associated with our production of materials for the upcoming litigation.  Offsetting the increases in selling, general and administrative expenses for the six months ended November 30, 2007 as compared to the six months ended November 30, 2006, were decreases amounting to approximately $85,000 for public relations expenses.

Settlement and license expenses amounting to $419,000 were recorded for the six months ended November 30, 2007 relating to royalties payable resulting from an agreement with Fish (see Note 4 to our condensed consolidated financial statements for more information).  For the six months ended November 30, 2006, $6,300,000 was recorded related to the Fish agreement.

Our other income and expenses for the six months ended November 30, 2007 and 2006 included equity in the earnings of PDS. The investment is accounted for in accordance with the equity method of accounting for investments. Our investment in PDS for the six months ended November 30, 2007  provided net income after expenses in the amount of approximately $4,285,000 as compared to net income after expenses of $18,745,000 for the six months ended November 30, 2006. Total other income and expense for the six  months ended November 30, 2007 amounted to net other income of approximately $5,210,000 compared with total other income and expense for the six months ended November 30, 2006 of net other income amounting to approximately $19,052,000. Interest income and other income increased from approximately $308,000 for the six months ended November 30, 2006 to approximately $776,000 for the six months ended November 30, 2007 as interest bearing account balances increased from cash received as distributions from our investment in PDS and we recognized other income of approximately $227,000 in connection with our reimbursement request billings to PDS for our prior period legal expenses incurred in connection with the patent litigation.  During the six months ended November 30, 2007, SSDI recognized $150,000 of other income in connection with the sale of a portion of its interest in Holocom MultiDomain Computers, LLC, now known as DataSecurus, LLC.

25


During the six months ended November 30, 2006, we recorded a provision for income taxes of $4,220,000 related to federal and California taxes.  During the six months ended November 30, 2007, we recorded a provision for income taxes of approximately $1,351,000 related to federal and California taxes.  Also, during the quarters ended November 30, 2006, and November 30, 2007, we utilized approximately $34,300,000 and $5,600,000, respectively, of our available federal net operating loss carry-forwards.  At November 30, 2007 we have utilized all of our remaining available federal net operating loss carry-forwards.   At May 31, 2007, we had utilized all of our state net operating loss carry-forwards of approximately $17,822,000.

We recorded net income for the six months ended November 30, 2006 of $4,108,275 compared with net income of $454,150 for the six months ended November 30, 2007.

Comparison of the Three Months Ended November 30, 2007 and Three Months Ended November 30, 2006.

Our revenues increased from approximately $19,000 for the three months ended November 30, 2006 to approximately $946,000 for the three months ended November 30, 2007. Our revenue amounts do not include income of approximately $6,675,000 from our investment in Phoenix Digital Solutions, LLC (“PDS”)for the three months ended November 30, 2006, or income of approximately $5,486,000 from our investment in Phoenix Digital Solutions, LLC for the three months ended November 30, 2007.  During the three months ended November 30, 2007 we recorded sales amounting to approximately $933,000 by our consolidated variable interest entity, SSDI, with cost of sales amounting to approximately $356,000. During the three months ended November 30, 2006 and 2007, we recognized maintenance fee revenues totaling approximately $6,250 and $6,250 in connection with an agreement with AMD Corporation during the 2005 fiscal year. The agreement called for maintenance fees totaling $100,000 connected with a license agreement for our Ignite technology; the license fee revenue is being recognized as revenue evenly over the four year period of the license. In addition during the three months ended November 30, 2007, we recorded sales of approximately $6,300 from the sale of microprocessor chips that we no longer market. Inventory associated with the sales of these microprocessor chips is carried at zero value.  During the three months ended November 30, 2006, we recorded sales of approximately $12,250 relating to the microprocessor chips.

Selling, general and administrative expenses increased from approximately $1,736,000 for the three months ended November 30, 2006 to approximately $1,986,000 for the three months ended November 30, 2007.  Legal expenses increased by approximately $190,000 for the three months ended November 30, 2007 compared with the three months ended November 30, 2006 and accounting expenses decreased by approximately $298,000 for the three months ended November 30, 2007 compared with the three months ended November 30, 2006.  The decrease was primarily due to restatement expenses incurred during the three months ended November 30, 2006. Salary costs and related expenses included non-cash expenses associated with the fair value of options granted during the period in accordance with SFAS No. 123R.  During the three months ended November 30, 2007, options were granted to our newly-appointed chief financial officer pursuant to terms of his employment contract, those option grants plus the related vesting on the grants resulted in non-cash compensation expense of approximately $38,000.  During the three months ended November 30, 2006, options were granted to employees resulting in non-cash compensation of approximately $184,000.  Board of director fees amounting to approximately $114,000 were paid during the three months ended November 30, 2007 as compared to $90,000 paid for the three months ended November 30, 2006.  Other salary expenses increased by approximately $261,000 for the three months ended November 30, 2007 as compared with the three months ended November 30, 2006 including approximately $288,000 in salaries and related expenses for SSDI during the three months ended November 30, 2007. Salary expenses for the parent company including wages, payroll taxes, employee benefits and expenses connected with 401(k) employer matching decreased by approximately $27,000 during the three months ended November 30, 2007 as compared with the three months ended November 30, 2006.  Travel and related expenses for the three months ended November 30, 2007 increased by approximately $56,000, an increase of approximately $9,000 for the parent company and an increase of $47,000 for SSDI.

26

 
Settlement and license expenses amounting to $389,000 were recorded for the three months ended November 30, 2007 relating to royalties payable resulting from an agreement with Fish (see Note 4 to our condensed consolidated financial statements for more information).  For the three months ended November 30, 2006, $6,300,000 was recorded related to the Fish agreement.

Our other income and expenses for the three months ended November 30, 2007 and 2006 included equity in the earnings of PDS. The investment is accounted for in accordance with the equity method of accounting for investments. Our investment in PDS for the three months ended November 30, 2007  provided net income after expenses in the amount of approximately $5,486,000 as compared to net income after expenses of $6,675,000 for the three months ended November 30, 2006. Total other income and expense for the three months ended November 30, 2007 amounted to net other income of approximately $5,786,000 compared with total other income and expense for the three months ended November 30, 2006 of net other income amounting to approximately $6,856,000. Interest income and other income increased from approximately $181,000 for the three months ended November 30, 2006 to approximately $301,000 for the three months ended November 30, 2007 as interest bearing account balances increased from cash received as distributions from our investment in PDS.

Liquidity and Capital Resources

Liquidity

Our cash, marketable securities and short-term investment balances decreased from approximately $25,955,000 as of May 31, 2007 to approximately $20,206,000 as of November 30, 2007. We also have restricted cash balances amounting to approximately $102,000 as of May 31, 2007 and approximately $50,000 as of November 30, 2007. Total current assets decreased from approximately $31,399,000 as of May 31, 2007 to approximately $22,559,000 as of November 30, 2007. Total current liabilities amounted to approximately $2,021,000 and approximately $6,115,000 as of May 31, 2007 and November 30, 2007, respectively. The change in our current position as of November 30, 2007 as compared with May 31, 2007 results in part from our utilization of cash to repurchase warrants and to purchase treasury stock, which amounted to $5,804,000, while not receiving cash distributions from PDS during the three months ended August 31, 2007.  Additionally, during the six months ended November 30, 2007, we utilized our remaining federal net operating losses for income tax purposes, resulting in a current tax liability of approximately $5,447,000 and causing our prepaid income taxes and deferred tax assets at May 31, 2007 to be reclassified to the current tax liability.  Total cash paid for income taxes during the six months ended November 30, 2007 was $3,958,000.  We also used $500,000 for the settlement of arbitration with  a former executive officer and director of the Company.

Cash Flows From Operating Activities

Cash used in operating activities for the six months ended November 30, 2007 was approximately $7,836,000 as compared with cash used in operating activities for the six months ended November 30, 2006 of approximately $2,949,000. The principal components of the current period amount were: net income of approximately $454,000, change in refundable income taxes of approximately $2,071,000 and a change in income  taxes payable of approximately $5,447,000.  These increases were partially offset by: equity in earnings of PDS of $4,285,000, change in deferred taxes of approximately $10,098,000, and changes in accounts payable and accrued expenses of approximately $1,352,000.

Cash Flows From Investing Activities

Cash used in investing activities was approximately $408,000 for the six months ended November 30, 2007 as compared to cash provided by investing activities of approximately $14,609,000 for the six months ended November 30, 2006. The decrease was primarily due to a reduction of distributions received from our investment in affiliate from $15,099,000 in 2006 to $7,738,000 in 2007.  Cash used during the six months ended November 30, 2007 also included $8,281,000 in net purchases of short-term investments and purchases of fixed assets of approximately $18,000.  The cash used during the six months ended November 30, 2007 was partially offset by proceeds of $100,000 received  by SSDI for the sale of a membership interest in DataSecurus, LLC and proceeds of $52,500 received from collateral accounts held on former officers’ credit cards that were cancelled.

27

 
Cash Flows From Financing Activities

Cash used in financing activities for the six months ended November 30, 2007 was approximately $5,786,000 as compared to approximately $3,927,000 for the six months ended November 30, 2006 primarily due to payments of approximately $3,043,000 to repurchase shares of our common stock for treasury and warrant repurchases of approximately $2,761,000 for the six months ended November 30, 2007. The cash used during the six months ended November 30, 2007 was partially offset by cash received of approximately $18,000 from the exercise of common stock options and warrants.

Capital Resources

Our current position as of November 30, 2007 is expected to provide the funds necessary to support our operations through at least the next twelve months.

Contractual Obligations and Committments

A summary of our outstanding contractual obligations at November 30, 2007 is as follows:
 
Contractual
Cash Obligations
 
Total
Amounts
Committed
 
 
1-3
Years
 
 
 
 
 
 
 
 
Operating leases - facilities
 
$
176,082
 
 
$
176,082
 

Recent Accounting Pronouncements

In July 2006, the FASB issued Interpretation No. 48, Accounting for Uncertainty in Income Taxes - an interpretation of FASB Statement No. 109 (“FIN 48”). This interpretation clarifies the application of SFAS No. 109, Accounting for Income Taxes, by defining criteria that an individual tax position must meet for any part of the benefit of that position to be recognized in a company’s financial statements and also provides guidance on measurement, derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition.  We adopted FIN 48 on June 1, 2007 and did not record any cumulative effect adjustment to retained earnings as a result of adopting FIN 48.  Interest and penalties, if any, related to unrecognized tax benefits are recorded in income tax expense.  As of June 1, 2007, we are subject to U.S. Federal income tax examinations for the tax years May 31, 1991 through May 31, 2007, and we are subject to state and local income tax examinations for the tax years May 31, 1999 through May 31, 2007 due to the carryover of net operating losses from prior years.

In September 2006, the FASB issued SFAS No. 157, Fair Value Measurements (“SFAS No. 157”).  SFAS No. 157 defines fair value, establishes a framework for measuring fair value in generally accepted accounting principals and expands disclosures about fair value measurements.  The statement does not require new fair value measurements, but is applied to the extent that other accounting pronouncements require or permit fair value measurements.  The statement emphasizes that fair value is a market-based measurement that should be determined based on the assumptions that market participants would use in pricing an asset or liability.  Companies that have assets and liabilities measured at fair value will be required to disclose information that enables the users of its financial statements to access the inputs used to develop those measurements.  The reporting entity is encouraged, but not required, to combine the fair value information disclosed under this statement with the fair value information disclosed under other accounting pronouncements.  SFAS No. 157 is effective for fiscal years beginning after November 15, 2007. We expect to adopt SFAS No. 157 on June 1, 2008.  We are currently assessing the impact the adoption of SFAS No. 157 will have on our consolidated financial statements.

28


In February 2007, the FASB issued SFAS No. 159, The Fair Value Option for Financial Assets and Financial Liabilities (“SFAS No. 159”). SFAS No. 159 permits entities to choose to measure at fair value many financial instruments and certain other items that are not currently required to be measured at fair value. The objective is to improve financial reporting by providing entities with the opportunity to mitigate volatility in reported earnings caused by measuring related assets and liabilities differently without having to apply complex hedge accounting provisions. SFAS No. 159 also establishes presentation and disclosure requirements designed to facilitate comparisons between entities that choose different measurement attributes for similar types of assets and liabilities. SFAS No. 159 does not affect any existing accounting literature that requires certain assets and liabilities to be carried at fair value. SFAS No. 159 does not establish requirements for recognizing and measuring dividend income, interest income, or interest expense. This Statement does not eliminate disclosure requirements included in other accounting standards. SFAS No. 159 is effective in fiscal years beginning after November 15, 2007. We are in the process of evaluating the provisions of the statement, but do not anticipate that the adoption of SFAS No. 159 will have a material impact on our consolidated financial statements.

In December 2007, the FASB issued SFAS No. 141(R), Business Combinations (“SFAS No. 141(R)”). SFAS No. 141(R) requires acquiring entities in a business combination to recognize the assets acquired and liabilities assumed in the transaction; establishes the acquisition-date fair value as the measurement objective for all assets acquired and liabilities assumed; and requires the acquirer to disclose to investors the information they need to evaluate and understand the nature and financial effect of the business combination. SFAS No. 141(R) is effective in fiscal years beginning after December 15, 2008. We expect to adopt SFAS No. 141(R) on June 1, 2009.  We are currently assessing the impact the adoption of SFAS No. 141(R) will have on our consolidated financial statements.

In December 2007, the FASB issued SFAS No. 160, Noncontrolling Interests in Consolidated Financial Statements (“SFAS No. 160”). SFAS No. 160 requires entities to report noncontrolling (minority) interests in subsidiaries as equity in the consolidated financial statements . SFAS No. 160 is effective in fiscal years beginning after December 15, 2008. We expect to adopt SFAS No. 160 on June 1, 2009.  We are currently assessing the impact the adoption of SFAS No. 160 will have on our consolidated financial statements.

Risk Factors

We urge you to carefully consider the following discussion of risks as well as other information regarding our common stock. We believe the following to be our most significant risk factors as of the date this report is being filed. The risks and uncertainties described below are not the only ones we face.

We Have Reported Substantial Income In 2006 and 2007 Which May Not Be Indicative Of Our Future Income

During fiscal 2007 and 2006, we entered into license agreements, directly and through our joint venture with Technology Properties Limited. Because of the uncertain nature of the negotiations that lead to license revenues, pending litigation with companies which we allege have infringed on our patent portfolio, the possibility of legislative action regarding patent rights, and the possible effect of new judicial interpretation of patent laws, we cannot predict the amount of future revenues from such agreements, or whether there will be future revenues from license agreements at all.

We Are Dependent Upon A Joint Venture In Which We Are A Passive Partner For Substantially All Of Our Income

In June of 2005, we entered into a joint venture with Technology Properties Limited, pursuant to which Technology Properties Limited is responsible for the licensing and enforcement of our microprocessor patent portfolio. This joint venture has been the source of virtually all of our income since June of 2005. Therefore, in light of the absence of significant revenue from other sources, we should be regarded as entirely dependent on the success or failure of the licensing and prosecution efforts of Technology Properties Limited on behalf of the joint venture. Sales of our microprocessor products and data security products have resulted in limited revenues. Our other product lines are no longer being actively marketed, and also only generate limited and sporadic sales.

29

 
Our Limited Sales And Marketing Capabilities Have Affected Our Revenue

We currently have limited marketing capabilities and may need to hire additional sales and marketing personnel. We may not be able to recruit, train, or retain qualified personnel to sell and market our products. We also may not be able to develop a successful sales and marketing strategy. We also have very limited marketing experience. Any marketing efforts we undertake may not be successful and may not result in any significant sales of our products.

We May Experience Difficulties In The Completion Of Our Development Stage Products

Our technologies and products are in various stages of development. We do not currently have in-house development personnel, nor have we retained independent researchers. Therefore, our development stage products may not be completed on a timely basis or at all. Additionally, even if we do recommence our development activities, our development stage products may not be completed due to the inherent risks of new product and technology development, limitations on financing, competition, obsolescence, the absence or loss of key personnel and other factors. Although we have licensed some of our technology at its current stage of development, we may not continue to be able to do so and any revenues generated from licensing may not be sufficient to support operations at their current level. Also, unanticipated technical obstacles can arise at any time and result in lengthy and costly delays or in a determination that further development is not feasible.

Changes In Our Relationships With Companies In Which We Hold Less Than A Majority Interest Could Change The Way We Account For Such Interests In The Future.

We hold a minority interest in a company (Scripps Secured Data, Inc.) to which we provide financing. Under the applicable provisions of accounting principles generally accepted in the United States of America, including FIN 46(R), we currently consolidate the financial statements and results of operations of this company into our consolidated financial statements and results of operations, and record the equity interest that we do not own as a minority interest. For our other investment (Phoenix Digital Solutions, LLC), accounted for under the equity method, we record as part of other income or expense our share of the increase or decrease in the equity of the company in which we have invested. It is possible that, in the future, our relationships and/or our interests in or with this consolidated entity and equity method investee could change. Such potential future changes could result in deconsolidation or consolidation of such entities, as the case may be, which could result in changes in our reported results.

We Have Settled A Legal Dispute Which Could Affect Our Future Results Of Operations And Working Capital Position

We were sued by a co-inventor of the technology underlying our microprocessor patent portfolio with regard to proceeds we received as a consequence of recently signed license agreements. On February 14, 2007, we finalized a settlement of this litigation. This settlement required us to pay the co-inventor $6,400,000 and requires us to pay up to $2,000,000 from the proceeds we receive from future licensing transactions. As of the date of this filing, we have paid $1,582,000 of the $2,000,000 obligation for future licensing transaction proceeds required under the settlement agreement. These payments have resulted, and will result, in a reduction of our net income in the current fiscal year and future quarters until our obligations under the settlement have been fulfilled.

30


A Successful Challenge To Our Intellectual Property Rights Would Have A Significant And Adverse Effect On Us

A successful challenge to our ownership of our technology or the proprietary nature of our intellectual property would materially damage our business prospects. We rely on a combination of patents, trademarks, copyrights, trade secret laws, confidentiality procedures and licensing arrangements to protect our intellectual property rights. We currently have seven U.S. patents, one European patent, and one Japanese patent issued. Any issued patent may be challenged and invalidated. Patents may not be issued for any of our pending applications. Any claims allowed from existing or pending patents may not be of sufficient scope or strength to provide significant protection for our products. Patents may not be issued in all countries where our products can be sold so as to provide meaningful protection or any commercial advantage to us. Our competitors may also be able to design around our patents.

Vigorous protection and pursuit of intellectual property rights or positions characterize the fiercely competitive semiconductor industry, which has resulted in significant and often protracted and expensive litigation. Therefore, our competitors and others may assert that our technologies or products infringe on their patents or proprietary rights. Persons we believe are infringing our patents are likely to vigorously defend their actions and assert that our patents are invalid. Problems with patents or other rights could increase the cost of our products or delay or preclude new product development and commercialization by us, and limit future license revenue. If infringement claims against us are deemed valid or if our infringement claims are successfully opposed, we may not be able to obtain appropriate licenses on acceptable terms or at all. Litigation could be costly and time-consuming but may be necessary to protect our future patent and/or technology license positions or to defend against infringement claims.  Parties have petitioned the U. S. Patent and Trademark Office to re-examine certain of our patents. An adverse decision in litigation or in the re-examination process would have a very significant and adverse effect on our business.

On December 18, 2007 we announced that a resolution was reached in two patent infringement lawsuits in the U.S. District Courts in the Eastern District of Texas and the Northern District of California.  There are no assurances that the resolution will favorably impact, or that it will not impair, our ability to assert our technology rights in the future.

If A Large Number Of Our Shares Are Sold All At Once Or In Blocks, The Market Price Of Our Shares Would Most Likely Decline

Our warrant holders are not restricted in the price at which they can sell common stock acquired through the exercise of warrants. Shares sold at a price below the current market price at which the common stock is trading may cause the market price to decline.

The Market For Our Stock Is Subject To Rules Relating To Low-Priced Stock (“Penny Stock”) Which May Limit Our Ability To Raise Capital

Our common stock is currently listed for trading in the National Association of Securities Dealers (“NASD”) Over-The-Counter Bulletin (“OTC”) Board Market and is subject to the “penny stock rules” adopted pursuant to Section 15(g) of the Exchange Act. In general, the penny stock rules apply to non-NASDAQ or non-national stock exchange companies whose common stock trades at less than $5.00 per share or which have tangible net worth of less than $5,000,000 ($2,000,000 if the company has been operating for three or more years). Such rules require, among other things, that brokers who trade “penny stock” on behalf of persons other than “established customers” complete certain documentation, make suitability inquiries of investors and provide investors with certain information concerning trading in the security, including a risk disclosure document, quote information, broker’s commission information and rights and remedies available to investors in penny stocks. Many brokers have decided not to trade “penny stock” because of the requirements of the penny stock rules, and as a result, the number of broker-dealers willing to act as market makers in such securities is limited. The “penny stock rules,” therefore, may have an adverse impact on the market for our common stock and may affect our ability to raise additional capital if we decide to do so.

31


Our Share Price Could Decline As A Result Of Short Sales

When an investor sells stock that he does not own, it is known as a short sale. The seller, anticipating that the price of the stock will go down, intends to buy stock to cover his sale at a later date. If the price of the stock goes down, the seller will profit to the extent of the difference between the price at which he originally sold it less his later purchase price. Short sales enable the seller to profit in a down market. Short sales could place significant downward pressure on the price of our common stock. Penny stocks which do not trade on an exchange, such as our common stock, are particularly susceptible to short sales.

Our Future Success Depends In Significant Part Upon The Continued Services Of Our Key Senior Management

Our future success depends in significant part upon the continued services of our key senior management personnel. The competition for highly qualified personnel is intense, and we may not be able to retain our key managerial employees or attract and retain additional highly qualified technical and managerial personnel in the future. None of our employees are represented by a labor union, and we consider our relations with our employees to be good. None of our employees are covered by key man life insurance policies.

Item 3. Quantitative and Qualitative Disclosures About Market Risk
 
Interest rate risk

Our exposure to market risk for changes in interest rates relates primarily to our short-term investments.  At November 30, 2007 approximately $7.5 million of our short-term investment balance consisted of auction  rate securities.  The auction rate securities are adjustable-rate securities with interest rates that are reset periodically by bidders through Dutch auctions generally conducted every 7 to 90 days by a trust company or broker/dealer on behalf of the issuer.  We believe these securities are highly liquid investments through the related auctions; however, the collateralizing securities have long-term maturities.  All of our auction rate securities are rated AAA by Moody’s, Fitch and S & P ratings.  Our short-term investments are intended to establish a high-quality portfolio that preserves principal, meets liquidity needs, avoids inappropriate concentrations and delivers an appropriate yield in relationship to our investment guidelines.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures
 
As required by Rule 13a-15(e) under the Exchange Act, as of November 30, 2007, the end of the period to which this quarterly report relates, we have carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures.  This evaluation was carried out under the supervision and with the participation of our management, including our Chief Executive Officer and our Chief Financial Officer.
 
Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our report filed or submitted under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms.  Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed under the Exchange Act is accumulated and communicated to management, including the Chief Executive Officer and Chief Financial Officer as appropriate, to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.  Based on the evaluation of our disclosure controls and procedures as of November 30, 2007, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective.
 
32

 
Changes in Internal Control over Financial Reporting
 
There were no changes to our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during our most recently completed fiscal quarter that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
 
PART II- OTHER INFORMATION

Item 1. Legal Proceedings

On December 18, 2007 all remaining parties to the litigation announced that a resolution was reached in the patent infringement lawsuits.  The terms of the settlement included the grant by TPL of rights under the Moore Microprocessor Patent Portfolio to NEC Electronics America, Toshiba, Matsushita and JVC and their respective subsidiaries in the form of license agreements.  The parties have agreed that the details of the settlement are confidential.

The Company had been in arbitration with Lowell Giffhorn, a former executive officer and a former director of the Company over matters related to the termination of Mr. Giffhorn's employment with the Company.   On November 1, 2007, the Company and Mr. Giffhorn reached a settlement where Mr. Giffhorn was given $500,000 and 200,000 shares of restricted Company stock in exchange for a comprehensive release of all claims against the Company.

Item 1A. Risk Factors

No material changes from the risk factors contained in our 10-K for the year ended May 31, 2007.  Please see Part I, Item 2, above, for our risk factors.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

On April 28, 2006, our Board of Directors authorized a stock repurchase program.  We commenced the program in July 2006 and plan to repurchase outstanding shares of our common stock on the open market from time to time.  As part of the program, we purchased 737,181 shares of our common stock at an aggregate cost of $317,128 during the three months ended November 30, 2007.

Following is a summary of all repurchases by the Company of its common stock during the three month period ended November 30, 2007:

Period
Total
 Number of Shares Purchased
Average Price Paid per
Share
Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs
       
September 1 – 30, 2007
 
368,960
$
0.40
368,960
October 1 – 31, 2007
 
368,221
$
0.46
368,221
November 1 – 30, 2007
 
-
$
-
-
Total
 
737,181
$
0.43
737,181

On November 5, 2007 we issued 200,000 shares of our common stock to a former officer in connection with  a legal settlement.

Item 3. Defaults Upon Senior Securities

None.

33

 
Item 4. Submission of Matters to a Vote of Security Holders

At our fiscal 2007 Annual Meeting of Shareholders held on October 23, 2007, the following individuals were elected to the Board of Directors of the Company: David H. Pohl, Carlton M. Johnson, Jr., Helmut Falk, Jr., Gloria H. Felcyn, James L. Turley, and Harry L. Tredennick.

The following proposals were approved at our Annual Meeting of Shareholders:
 
1.
Proposal to ratify management’s selection of KMJ Corbin & Company LLP as the Company’s independent auditors:
 
Votes For
 
Votes Against
 
Votes Abstaining
299,939,156
 
2,296,488
 
8,814,305

2.
Election of Directors:

Director
 
Votes For
 
Votes Abstaining
and/or Against
David H. Pohl
 
292,817,894
 
18,232,056
Carlton M. Johnson, Jr.
 
291,285,030
 
19,764,920
Helmut Falk, Jr.
 
292,352,425
 
18,697,525
Gloria H. Felcyn
 
292,268,984
 
18,780,966
James L. Turley
 
300,843,675
 
10,206,275
Harry L. Tredennick
 
300,916,854
 
10,133,096

Item 5. Other Information

None.

Item 6. Exhibits

Those exhibits marked with an asterisk (*) refer to exhibits filed herewith. The other exhibits are incorporated herein by reference, as indicated in the following list.
 
Exhibit No.
Document
   
2.1
 
Agreement to Exchange Technology for Stock in the Company, incorporated by reference to Exhibit 2.1 to Form 8-K dated August 10, 1989 (Commission file No. 33-23143-FW)
 
2.2
 
Assets Purchase Agreement and Plan of Reorganization dated June 22, 1994, among the Company, nanoTronics Corporation and Helmut Falk, incorporated by reference to Exhibit 10.4 to Form 8-K dated July 6, 1994 (Commission file No. 000-22182)
 
2.2.1
 
Amendment to Development Agreement dated April 23, 1996 between the Company and Sierra Systems, incorporated by reference to Exhibit 2.2.1 to Pre-Effective Amendment No. 1 to Registration Statement on Form SB-2 filed April 29, 1996 (Commission file No. 333-01765)
 

34


2.3
 
Form of Exchange Offer dated December 4, 1996 between the Company and certain shareholders of Metacomp, Inc., incorporated by reference to Exhibit 2.3 to Form 8-K filed January 9, 1997 (Commission file No. 000-22182)
 
2.4
 
Letter of Transmittal to Accompany Shares of Common Stock of Metacomp, Inc. Tendered Pursuant to the Exchange Offer Dated December 4, 1996, incorporated by reference to Exhibit 2.4 to Form 8-K filed January 9, 1997 (Commission file No. 000-22182)
 
3.1
 
Original Articles of incorporation of the Company’s predecessor, Patriot Financial Corporation, incorporated by reference to Exhibit 3.1 to registration statement on Form S-18, (Commission file No. 33-23143-FW)
 
3.2
 
Articles of Amendment of Patriot Financial Corporation, as filed with the Colorado Secretary of State on July 21, 1988, incorporated by reference to Exhibit 3.2 to registration statement on Form S-18, (Commission file No. 33-23143-FW)
 
3.3
 
Certificate of Incorporation of the Company, as filed with the Delaware Secretary of State on March 24, 1992, incorporated by reference to Exhibit 3.3 to Form 8-K dated May 12, 1992 (Commission file No. 33-23143-FW)
 
 3.3.1
 
Certificate of Amendment to the Certificate of Incorporation of the Company, as filed with the Delaware Secretary of State on April 18, 1995, incorporated by reference to Exhibit 3.3.1 to Form 10-KSB for the fiscal year ended May 31, 1995 (Commission file No. 000-22182)
 
3.3.2
 
Certificate of Amendment to the Certificate of Incorporation of the Company, as filed with the Delaware Secretary of State on June 24, 1997, incorporated by reference to Exhibit 3.3.2 to Form 10-KSB for the fiscal year ended May 31, 1997, filed July 18, 1997 (Commission file No. 000-22182)
 
3.3.3
 
Certificate of Amendment to the Certificate of Incorporation of the Company, as filed with the Delaware Secretary of State on April 28, 2000, incorporated by reference to Exhibit 3.3.3 to Registration Statement on Form S-3 filed May 5, 2000 (Commission file No. 333-36418)
 
3.3.4
 
Certificate of Amendment to the Certificate of Incorporation of the Company, as filed with the Delaware Secretary of State on May 6, 2002, incorporated by reference to Exhibit 3.3.4 to Registration Statement on Form S-3 filed June 27, 2002 (Commission file No. 333-91352)
 
3.3.5
 
Certificate of Amendment to the Certificate of Incorporation of the Company, as filed with the Delaware Secretary of State on October 16, 2003, incorporated by reference to Exhibit 3.3.5 to Registration Statement on Form SB-2 filed May 21, 2004 (Commission file No. 333-115752)
 
3.4
Articles and Certificate of Merger of Patriot Financial Corporation into the Company dated May 1, 1992, with Agreement and Plan of Merger attached thereto as Exhibit A, incorporated by reference to Exhibit 3.4 to Form 8-K dated May 12, 1992 (Commission file No. 33-23143-FW)
 
3.5
Certificate of Merger issued by the Delaware Secretary of State on May 8, 1992, incorporated by reference to Exhibit 3.5 to Form 8-K dated May 12, 1992 (Commission file No. 33-23143-FW)

35



3.6
Certificate of Merger issued by the Colorado Secretary of State on May 12, 1992, incorporated by reference to Exhibit 3.6 to Form 8-K dated May 12, 1992 (Commission file No. 33-23143-FW)
 
3.7
Bylaws of the Company, incorporated by reference to Exhibit 3.7 to Form 8-K dated May 12, 1992 (Commission file No. 33-23143-FW)
 
4.1
Specimen common stock certificate, incorporated by reference to Exhibit 4.1 Form 8-K dated May 12, 1992 (Commission file No. 33-23143-FW)

4.2
1996 Stock Option Plan of the Company dated March 25, 1996 and approved by the Shareholders on May 17, 1996, incorporated by reference to Exhibit 10.13 to Pre-Effective Amendment No. 2 to Registration Statement on Form SB-2 filed May 23, 1996 (Commission file No. 333-01765)
 
4.3
2001 Stock Option Plan of the Company dated February 21, 2001 incorporated by reference to Exhibit 4.19 to Registration Statement on Form S-8 filed March 26, 2001 (Commission file No. 333-57602)
 
4.4
2003 Stock Option Plan of the Company dated July 2, 2003 incorporated by reference to Exhibit 4.27 to Registration Statement on Form S-8 filed September 4, 2003 (Commission file No. 333-108489)
 
4.5
2006 Stock Option Plan of the Company dated March 31, 2006 incorporated by reference to Exhibit 4.19 to Registration Statement on Form S-8 filed June 20, 2006 (Commission file No. 333-135156)
 
4.6
Approval Rights Agreement and Termination of Antidilution Agreement and Addendum to Warrants dated October 10, 2006, incorporated by reference to Exhibit 4.29 to Form 10-KSB for the fiscal year ended May 31, 2006, filed on October 13, 2006 (Commission file No. 000-22182)
 
10.1
Employment Agreement dated June 5, 2007 by and between the Company and James Turley, incorporated by reference to Exhibit 10.1 to Form 8-K filed June 8, 2007 (Commission file No. 000-22182)
 
10.2
Employment Agreement dated September 17, 2007 by and between the Company and Clifford Flowers, incorporated by reference to Exhibit 10.1 to Form 8-K filed September 19, 2007 (Commission file No. 000-22182)
 
31.1*
 
Certification of James L. Turley, CEO, pursuant to Rule 13a–14(a)/15d–14(a)
31.2*
 
Certification of Clifford L. Flowers, CFO, pursuant to Rule 13a–14(a)/15d–14(a)
32.1*
 
Certification of James L. Turley, CEO, pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code
 
32.2*
 
Certification of Clifford L. Flowers, CFO, pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code

36


SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
DATED:  January 9, 2008
PATRIOT SCIENTIFIC CORPORATION
 
 
/S/ JAMES L. TURLEY                                     
James L. Turley
Chief Executive Officer
 

In accordance with the Exchange Act, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
 
Signature
Title
Date
 
/S/ JAMES L. TURLEY                               
James L. Turley
President, Chief Executive Officer, and Director
January 9, 2008
     
/S/ CLIFFORD L. FLOWERS                     
Clifford L. Flowers
Chief Financial Officer and Principal Accounting Officer
January 9, 2008
     
/S/ DAVID H. POHL                                   
David H. Pohl
Chairman
January 9, 2008
     
/S/ CARLTON M. JOHNSON                   
Carlton M. Johnson
Director
January 9, 2008
     
/S/ GLORIA H. FELCYN                            
Gloria H. Felcyn
Director
January 9, 2008
     
/S/ HELMUT FALK, JR.                            
Helmut Falk, Jr.
Director
January 9, 2008
     
/S/ HARRY L. TREDENNICK                   
Harry L. Tredennick
Director
January 9, 2008
 
37